# EDGAR Filing Document

**Accession Number:** 0000039368
**File Stem:** 0001437749-25-029858
**Filing Date:** 2025-9
**Character Count:** 157659
**Document Hash:** d42d4b07ce23ad7c8f78b8a806b3ac29
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-029858.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0001437749-25-029858

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 84

**CONFORMED PERIOD OF REPORT**: 20250830

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FULLER H B CO
- **CENTRAL INDEX KEY:** 0000039368
- **STANDARD INDUSTRIAL CLASSIFICATION:** ADHESIVES & SEALANTS [2891]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 410268370
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 1129

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-09225
- **FILM NUMBER:** 251342595

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 WILLOW LAKE BLVD
- **CITY:** ST PAUL
- **STATE:** MN
- **ZIP:** 55110-5132
- **BUSINESS PHONE:** 6126453401

**MAIL ADDRESS:**
- **STREET 1:** 1200 WILLOW LAKE BLVD
- **CITY:** ST PAUL
- **STATE:** MN
- **ZIP:** 55110-5132

?xml version='1.0' encoding='ASCII'? ful20250703_10q.htm

[**Table of Contents**](#toc)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended August 30, 2025**

**OR**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the transition period from** <u>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**</u> **to** <u>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**</u><u>**.**</u>

<u>**Commission file number: 001-09225**</u>

**H.B. FULLER COMPANY**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Minnesota** | **41-0268370** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **1200 Willow Lake Boulevard, St. Paul, Minnesota** | **55110-5101** |
| (Address of principal executive offices) | (Zip Code) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

Registrant's telephone number, including area code: **(651) 236-5900**

**Not Applicable**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>**Title of each class**</u> | <u>**Trading Symbol**</u> | <u>**Name of each exchange on which registered**</u> |
| Common Stock, par value $1.00 per share | &nbsp;&nbsp;&nbsp;&nbsp; FUL | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

---

| | |
|:---|:---|
| Large accelerated filer ☒ | Accelerated filer ☐ |
| Non-accelerated filer ☐ | Smaller reporting company ☐ |
|  | Emerging growth company ☐ |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

[**Table of Contents**](#toc)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b) of the Exchange Act. Yes ☐ No ☒

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PROCEEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

APPLICABLE ONLY TO CORPORATE ISSUERS

The number of shares outstanding of the Registrant's Common Stock, par value $1.00 per share, was 54,088,889 as of September 19, 2025

.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**H.B. Fuller Company**

**Quarterly Report on Form 10-Q**

**Table of Contents**

---

| | | |
|:---|:---|:---|
|  |  | Page |
| [**PART 1. FINANCIAL INFORMATION**](#part1) | [**PART 1. FINANCIAL INFORMATION**](#part1) |  |
| ITEM 1. | [FINANCIAL STATEMENTS (Unaudited)](#part1) | [4](#part1) |
|  | [Consolidated Statements of Income for the three and nine months ended August 30, 2025 and August 31, 2024](#part1) | [4](#part1) |
|  | [Consolidated Statements of Comprehensive Income for the three and nine months ended August 30, 2025 and August 31, 2024](#compinc) | [5](#compinc) |
|  | [Consolidated Balance Sheets as of August 30, 2025 and November 30, 2024](#conbal) | [6](#conbal) |
|  | [Consolidated Statements of Total Equity for the three and nine months ended August 30, 2025 and August 31, 2024](#equity) | [7](#equity) |
|  | [Consolidated Statements of Cash Flows for the nine months ended August 30, 2025 and August 31, 2024](#flows) | [8](#flows) |
|  | [Notes to Consolidated Financial Statements](#notes) | [9](#notes) |
| ITEM 2. | [MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#mda) | [25](#mda) |
| ITEM 3. | [QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#qqd) | [39](#qqd) |
| ITEM 4. | [CONTROLS AND PROCEDURES](#contpro) | [39](#contpro) |
| [**PART II. OTHER INFORMATION**](#part2) | [**PART II. OTHER INFORMATION**](#part2) | [40](#part2) |
| ITEM 1. | [LEGAL PROCEEDINGS](#legal) | [40](#legal) |
| ITEM 1A. | [RISK FACTORS](#risk) | [40](#risk) |
| ITEM 2. | [UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#unreg) | [41](#unreg) |
| ITEM 6. | [EXHIBITS](#exhibits) | [41](#exhibits) |
| [SIGNATURES](#sigs) | [SIGNATURES](#sigs) | [42](#sigs) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

<u>**PART I. FINANCIAL INFORMATION**</u>

<u>**Item 1. Financial Statements**</u>

**H.B. FULLER COMPANY AND SUBSIDIARIES**

**Consolidated Statements of Income**

(In thousands, except per share amounts)

(Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30,*** | ***August 31,*** | ***August 30,*** | ***August 31,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| **Net revenue** | $**892043** | $917927 | $**2578801** | $2645452 |
| Cost of sales | **(606929)** | (642198) | **(1780228)** | (1848435) |
| Gross profit | **285114** | 275729 | **798573** | 797017 |
| Selling, general and administrative expenses | **(174974)** | (171388) | **(541942)** | (525204) |
| Other income, net | **5308** | 2148 | **15655** | 7282 |
| Interest expense | **(33630)** | (35288) | **(100536)** | (99504) |
| Interest income | **1110** | 1092 | **3064** | 3597 |
| **Income before income taxes and income from equity method investments** | **82928** | 72293 | **174814** | 183188 |
| Income taxes | **(16527)** | (18264) | **(55198)** | (48496) |
| Income from equity method investments | **832** | 1310 | **2726** | 2955 |
| **Net income including non-controlling interest** | **67233** | 55339 | **122342** | 137647 |
| Net (income) loss attributable to non-controlling interest | **(73)** | 22 | **(106)** | (32) |
| **Net income attributable to H.B. Fuller** | $**67160** | $55361 | $**122236** | $137615 |
| **Earnings per share attributable to H.B. Fuller common stockholders:** |  |  |  |  |
| Basic | $**1.23** | $1.01 | $**2.24** | $2.51 |
| Diluted | $**1.22** | $0.98 | $**2.21** | $2.43 |
| **Weighted-average common shares outstanding:** |  |  |  |  |
| Basic | **54428** | 54975 | **54623** | 54874 |
| Diluted | **55162** | 56650 | **55381** | 56620 |

---

See accompanying Notes to Unaudited Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**H.B. FULLER COMPANY AND SUBSIDIARIES**

**Consolidated Statements of Comprehensive Income**

(In thousands)

(Unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30,*** | ***August 31,*** | ***August 30,*** | ***August 31,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| **Net income including non-controlling interest** | $**67233** | $55339 | $**122342** | $137647 |
| Other comprehensive income (loss) |  |  |  |  |
| Foreign currency translation | **36962** | 33355 | **139626** | (12932) |
| Defined benefit pension plans adjustment, net of tax | **158** | 1270 | **429** | 3808 |
| Interest rate swaps, net of tax | **(3347)** | (25744) | **(6920)** | (18013) |
| Net investment hedges, net of tax | **(14998**) | (8231) | **(53453)** | (4318) |
| **Other comprehensive income (loss)** | **18775** | 650 | **79682** | (31455) |
| Comprehensive income | **86008** | 55989 | **202024** | 106192 |
| Less: Comprehensive income attributable to non-controlling interest | **42** | 9 | **140** | 22 |
| **Comprehensive income attributable to H.B. Fuller** | $**85966** | $55980 | $**201884** | $106170 |

---

See accompanying Notes to Unaudited Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

**H.B. FULLER COMPANY AND SUBSIDIARIES**

**Consolidated Balance Sheets**

(In thousands, except share and per share amounts)

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | ***August 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** |
| **Assets** |  |  |
| **Current assets:** |  |  |
| Cash and cash equivalents | $**122458** | $169352 |
| Trade receivables (net of allowances of $11,661 and $11,621, as of August 30, 2025 and November 30, 2024, respectively) | **563579** | 558336 |
| Inventories | **502956** | 467498 |
| Other current assets | **111752** | 104019 |
| **Total current assets** | **1300745** | 1299205 |
| Property, plant and equipment | **1913345** | 1864558 |
| Accumulated depreciation | **(1023758)** | (982631) |
| **Property, plant and equipment, net** | **889587** | 881927 |
| Goodwill | **1681887** | 1532221 |
| Other intangibles, net | **829430** | 770226 |
| Other assets | **464453** | 449665 |
| **Total assets** | $**5166102** | $4933244 |
| **Liabilities, non-controlling interest and total equity** |  |  |
| **Current liabilities** |  |  |
| Notes payable | $**-** | $587 |
| Trade payables | **459409** | 491435 |
| Accrued compensation | **90283** | 106005 |
| Income taxes payable | **18774** | 24225 |
| Other accrued expenses | **105766** | 97038 |
| **Total current liabilities** | **674232** | 719290 |
| Long-term debt | **2080470** | 2010052 |
| Accrued pension liabilities | **56188** | 51755 |
| Other liabilities | **396240** | 322299 |
| **Total liabilities** | $**3207130** | $3103396 |
| Commitments and contingencies (Note 13) |  |  |
| **Equity** |  |  |
| H.B. Fuller stockholders' equity: |  |  |
| Preferred stock (no shares outstanding) shares authorized – 10,045,900 | **-** |  |
| Common stock, par value $1.00 per share, shares authorized – 160,000,000, shares outstanding – 54,043,300 and 54,657,103 as of August 30, 2025 and November 30, 2024, respectively | $**54043** | $54657 |
| Additional paid-in capital | **288195** | 322636 |
| Retained earnings | **2009152** | 1924761 |
| Accumulated other comprehensive loss | **(393747)** | (473395) |
| Total H.B. Fuller stockholders' equity | **1957643** | 1828659 |
| Non-controlling interest | **1329** | 1189 |
| **Total equity** | **1958972** | 1829848 |
| **Total liabilities, non-controlling interest and total equity** | $**5166102** | $4933244 |

---

See accompanying Notes to Unaudited Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

**H.B. FULLER COMPANY AND SUBSIDIARIES**

**Consolidated Statements of Total Equity**

(In thousands)

(Unaudited)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***H.B. Fuller Company Shareholders*** | ***H.B. Fuller Company Shareholders*** | ***H.B. Fuller Company Shareholders*** | ***H.B. Fuller Company Shareholders*** |  |  |
|  |  |  |  | ***Accumulated*** |  |  |
|  |  | ***Additional*** |  | ***Other*** |  |  |
|  | ***Common*** | ***Paid-in*** | ***Retained*** | ***Comprehensive*** | ***Non-Controlling*** |  |
|  | ***Stock*** | ***Capital*** | ***Earnings*** | ***Income (Loss)*** | ***Interest*** | ***Total*** |
| **Balance at November 30, 2024** | $**54657** | $**322636** | $**1924761** | $**(473395)** | $**1189** | $**1829848** |
| Comprehensive income (loss) | **-** | **-** | **13248** | **(15026)** | **33** | **(1745**) |
| Dividends | **-** | **-** | **(12285)** | **-** | **-** | **(12285)** |
| Stock option exercises | **33** | **1351** | **-** | **-** | **-** | **1384** |
| Share-based compensation plans and other, net | **229** | **5307** | **-** | **-** | **-** | **5536** |
| Repurchases of common stock | **(729)** | **(43648)** | **-** | **-** | **-** | **(44377)** |
| **Balance at March 1, 2025** | $**54190** | $**285646** | $**1925724** | $**(488421)** | $**1222** | $**1778361** |
| Comprehensive income | **-** | **-** | **41828** | **75868** | **65** | **117761** |
| Dividends | **-** | **-** | **(12767)** | **-** | **-** | **(12767)** |
| Stock option exercises | **32** | **1060** | **-** | **-** | **-** | **1092** |
| Share-based compensation plans and other, net | **33** | **7793** | **-** | **-** | **-** | **7826** |
| Repurchases of common stock | **(302)** | **(15986)** | **-** | **-** | **-** | **(16288)** |
| **Balance at May 31, 2025** | $**53953** | $**278513** | $**1954785** | $**(412553)** | $**1287** | $**1875985** |
| Comprehensive income | **-** | **-** | **67160** | **18806** | **42** | **86008** |
| Dividends | **-** | **-** | **(12793)** | **-** | **-** | **(12793)** |
| Stock option exercises | **87** | **2957** | **-** | **-** | **-** | **3044** |
| Share-based compensation plans and other, net | **4** | **6787** | **-** | **-** | **-** | **6791** |
| Repurchases of common stock | **(1)** | **(62)** | **-** | **-** | **-** | **(63)** |
| **Balance at August 30, 2025** | $**54043** | $**288195** | $**2009152** | $**(393747)** | $**1329** | $**1958972** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***H.B. Fuller Company Shareholders*** | ***H.B. Fuller Company Shareholders*** | ***H.B. Fuller Company Shareholders*** | ***H.B. Fuller Company Shareholders*** |  |  |
|  |  |  |  | ***Accumulated*** |  |  |
|  |  | ***Additional*** |  | ***Other*** |  |  |
|  | ***Common*** | ***Paid-in*** | ***Retained*** | ***Comprehensive*** | ***Non-Controlling*** |  |
|  | ***Stock*** | ***Capital*** | ***Earnings*** | ***Income (Loss)*** | ***Interest*** | ***Total*** |
| **Balance at December 2, 2023** | $54093 | $301485 | $1842507 | $(442880) | $708 | $1755913 |
| Comprehensive income (loss) | **-** | **-** | 30991 | (15909) | 12 | 15094 |
| Dividends | **-** | **-** | (11246) | **-** | **-** | (11246) |
| Stock option exercises | 200 | 8777 | **-** | **-** | **-** | 8977 |
| Share-based compensation plans and other, net | 225 | 5490 | **-** | **-** | **-** | 5715 |
| Repurchases of common stock | (80) | (6128) | **-** | **-** | **-** | (6208) |
| **Balance at March 2, 2024** | $54438 | $309624 | $1862252 | $(458789) | $720 | $1768245 |
| Comprehensive income (loss) |  |  | 51264 | (16156) | 1 | 35109 |
| Dividends |  |  | (12144) |  |  | (12144) |
| Stock option exercises | 189 | 9123 |  |  |  | 9312 |
| Share-based compensation plans and other, net | 81 | 7111 |  |  |  | 7192 |
| Repurchases of common stock | (200) | (15400) |  |  |  | (15600) |
| **Balance at June 1, 2024** | $54508 | $310458 | $1901372 | $(474945) | $721 | $1792114 |
| Comprehensive income |  |  | 55361 | 619 | 9 | 55989 |
| Dividends |  |  | (12353) |  |  | (12353) |
| Stock option exercises | 328 | 15553 |  |  |  | 15881 |
| Share-based compensation plans and other, net | 2 | 7650 |  |  |  | 7652 |
| Repurchases of common stock | (225) | (17337) |  |  |  | (17562) |
| **Balance at August 31, 2024** | $54613 | $316324 | $1944380 | $(474326) | $730 | $1841721 |

---

See accompanying Notes to Unaudited Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7

------

[**Table of Contents**](#toc)

**H.B. FULLER COMPANY AND SUBSIDIARIES**

**Consolidated Statements of Cash Flows**

(In thousands)

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30, 2025*** | ***August 31, 2024*** |
| **Cash flows from operating activities:** |  |  |
| Net income including non-controlling interest | $**122342** | $137647 |
| Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities: |  |  |
| Depreciation | **68314** | 66990 |
| Amortization | **64525** | 61723 |
| Deferred income taxes | **(39227)** | (45998) |
| Income from equity method investments, net of dividends received | **1045** | 622 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gain on insurance claims |  | (7264) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on equity investment |  | 1966 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on the sale of a business | **1515** |  |
| Loss on impairment of intangible asset | **478** |  |
| Gain on sale or disposal of assets | **(178)** | (501) |
| Share-based compensation | **18170** | 17662 |
| Pension and other post-retirement benefit plan activity | **(7047)** | (6671) |
| Change in assets and liabilities, net of effects of acquisitions: |  |  |
| Trade receivables, net | **(3336**) | 26373 |
| Inventories | **(42095)** | (62206) |
| Other assets | **(7530)** | (39025) |
| Trade payables | **(25764**) | 49705 |
| Accrued compensation | **(19230)** | (11566) |
| Other accrued expenses | **6856** | (5244) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income taxes payable | **(12993)** | (17873) |
| Other liabilities | **28622** | 856 |
| Foreign currency remeasurement | **2289** | 49591 |
| **Net cash provided by operating activities** | **156756** | 216787 |
| **Cash flows from investing activities:** |  |  |
| Purchased property, plant and equipment | **(94593)** | (112799) |
| Purchased businesses, net of cash acquired | **(162095)** | (274067) |
| Purchase of cost method investment | **(2549)** |  |
| Proceeds from sale of property, plant and equipment | **843** | 1048 |
| Proceeds from the sale of a business | **75727** |  |
| **Net cash used in investing activities** | **(182667)** | (385818) |
| **Cash flows from financing activities:** |  |  |
| Proceeds from issuance of long-term debt | **1114300** | 1732900 |
| Repayment of long-term debt | **(1053593)** | (1556135) |
| Payment of debt issuance costs | **(1047)** | (3493) |
| Net payment of notes payable | **(585)** | (1014) |
| Dividends paid | **(37559)** | (35440) |
| Proceeds from stock options exercised | **5519** | 34161 |
| Repurchases of common stock | **(60728)** | (39371) |
| **Net cash (used in) provided by financing activities** | **(33693**) | 131608 |
| Effect of exchange rate changes on cash and cash equivalents | **12710** | (10618) |
| **Net change in cash and cash equivalents** | **(46894)** | (48041) |
| Cash and cash equivalents at beginning of period | **169352** | 179453 |
| **Cash and cash equivalents at end of period** | $**122458** | $131412 |

---

See accompanying Notes to Unaudited Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8

------

[**Table of Contents**](#toc)

**H.B. FULLER COMPANY AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

(Amounts in thousands, except per share amounts)

(Unaudited)

**Note *1:* Basis of Presentation**

*Overview*

The accompanying unaudited interim Consolidated Financial Statements of H.B. Fuller Company and Subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and the instructions to Form *10*-Q and Article *10* of Regulation S-*X.* Accordingly, they do *not* include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial position and cash flows in conformity with U.S. generally accepted accounting principles. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments of a normal recurring nature considered necessary for the fair presentation of the results for the periods presented. Operating results for interim periods are *not* necessarily indicative of results that *may* be expected for the fiscal year as a whole.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from these estimates. These unaudited interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in our Annual Report on Form *10*-K for the year ended *November 30, 2024* as filed with the Securities and Exchange Commission.

*New Accounting Pronouncements*

In *November 20 24,* the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") *No. 2024*-*03,* Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic *220*-*40*): Disaggregation of Income Statement Expenses, which requires additional disclosure of the nature of expenses included in our Consolidated Financial Statements. Our effective date of this ASU is our fiscal year ending *December 2, 2028.* We are evaluating the effect this guidance will have on our Consolidated Finance Statements.

In *December 2023,* the FASB issued ASU *No. 2023*-*09,* Income Taxes (Topic *740*): Improvements to Income Tax Disclosures. This ASU requires entities to provide additional information in the rate reconciliation and additional disclosures about income taxes paid. This guidance requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state, and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. Our effective date of this ASU is our fiscal year ending *November 28, 2026.* We are evaluating the effect this guidance will have on our Consolidated Financial Statements.

In *November 2023,* the FASB issued ASU *No. 2023*-*07,* Segment Reporting (Topic *280*): Improvements to Reportable Segment Disclosures. This ASU requires enhanced disclosures regarding significant segment expenses and other segment items. The guidance requires public entities to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. Our effective date of this ASU is our fiscal year ending *November 29, 2025.* We are evaluating the effect this guidance will have on our Consolidated Financial Statements.

Recently issued accounting standards or pronouncements *not* disclosed above have been excluded as they are *not* relevant to the company.

*Supplier Finance Program*

We have agreements with *third* parties to provide supplier finance programs which facilitate participating suppliers' ability to finance payment obligations of the Company with designated *third*-party financial institutions. Participating suppliers *may,* at their sole discretion, elect to finance *one* or more payment obligations of the Company prior to their scheduled due dates at a discounted price to participating financial institutions. The Company has *no* economic interest in the sale of these suppliers' receivables and *no* direct financial relationship with the financial institutions concerning these services. The Company's obligations to its suppliers, including amounts due and scheduled payment dates, are *not* impacted by suppliers' decisions to finance amounts under these arrangements. The outstanding payment obligations that were confirmed as valid and remained outstanding as of *August 30, 2025*, and *November 30, 2024,* were approximately $8,122 and $5,233, respectively. These obligations under the Company's supplier finance programs are included in Accounts payable in the Consolidated Balance Sheets, and the associated payments are reflected in the cash flows from operating activities section of the Consolidated Statements of Cash Flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

[**Table of Contents**](#toc)

**Note *2:* Acquisitions and Divestiture**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *ND Industries Asia, Inc.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On *February 15, 2025,* we acquired the assets of ND Industries Asia, Inc. ("ND Industries Taiwan") for a purchase price of 271,860 Taiwan dollar, or approximately $8,310 which was funded through existing cash. Headquartered in Kaohsiung, Taiwan, ND Industries Taiwan is a leading provider of specialty adhesives and fastener locking and sealing solutions. The acquisition of ND Industries Taiwan is expected to accelerate the realization of our top growth priorities in Greater Asia, consistent with our strategy to proactively drive capital allocation to the highest margin, highest growth market segments within the functional coatings, adhesives, sealants and elastomer industry. The acquisition fair value measurement was preliminary as of *August 30, 2025* and includes goodwill of $2,422, other intangible assets of $2,400 and other net assets of $3,488. Goodwill represents expected synergies from combining ND Industries Taiwan with our existing business. Goodwill is deductible for tax purposes. ND Industries Taiwan is included in our Engineering Adhesives operating segment.

*GEM S.r.l. and Medifill Limited*

On *January 15, 2025,* we completed the acquisition of GEM S.r.l. ("GEM") and on *December 2, 2024,* we completed the acquisition of Medifill Limited (Medifill") for a total purchase price of 191,868 Euros, or approximately $196,990 which was funded through borrowings on our credit facility and existing cash. Included in the purchase price is a holdback to be paid in three annual tranches beginning one year after the date of acquisition. The fair value of the holdback was 28,170 Euros or approximately $28,922 at the date of acquisition. See Note *12* for more information on the fair value of the holdback.

Although they were independent transactions, the acquisitions of GEM and Medifill were accounted for as a single business combination under ASC *805,* as they were negotiated concurrently and are economically interdependent. Headquartered in Viareggio, Italy, GEM develops, produces and sells medical adhesives for wound closure in both surgical and topical applications. Headquartered in Dublin, Ireland, Medifill produces medical-grade cyanoacrylate adhesives tailored to the wound closure market for GEM. The acquisitions of GEM and Medifill establish a European headquarters for our Medical Adhesives Technologies business and European production capabilities for our medical adhesive offerings, further shifting our portfolio toward highly profitable, higher growth markets. The acquisition fair value measurement was preliminary as of *August 30, 2025* and includes goodwill of $90,198, other intangible assets of $104,723 and other net liabilities of $2,069. Goodwill represents expected synergies from combining GEM and Medifill with our existing business. Goodwill is *not* deductible for tax purposes. GEM and Medifill are included in our Hygiene, Health and Consumable Adhesives operating segment.

*HS Butyl Limited*

On *August 5, 2024,* we acquired HS Butyl Limited ("HS Butyl") for a purchase price of 18,342 British pounds, or approximately $23,428 which was funded through existing cash. This includes a holdback amount of 2,700 British pound sterling that will be paid on the *18*-month anniversary of the closing date. HS Butyl, headquartered in Lymington, England, is the United Kingdom's largest manufacturer and distributor of high-quality butyl tapes, which provide strong, permanent, watertight seals for a wide variety of applications within the construction, infrastructure, automotive and renewable energy industries. The acquisition of HS Butyl establishes our presence in the European waterproofing tape market, expanding our position as a solution provider to existing customers. It also expands our relevance to more markets and creates opportunities to deliver new, in-demand solutions for our customers, given the technology's relevance to multiple high-value applications. The acquisition fair value measurement was final as of *August 30, 2025* and includes other intangible assets of $6,974, goodwill of $3,805 and other net assets of $12,649. Goodwill represents expected synergies from combining HS Butyl with our existing business. Goodwill is *not* deductible for tax purposes. HS Butyl is included in our Building Adhesive Solutions operating segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

[**Table of Contents**](#toc)

*ND Industries, Inc.* 

On *May 20, 2024,* we acquired the assets of ND Industries, Inc. ("ND Industries") for a base purchase price of $254,037 which was funded through borrowings on our credit facility and existing cash. ND Industries, headquartered in Clawson, Michigan, is a leading provider of specialty adhesives and fastener locking and sealing solutions serving customers in the automotive, electronics, aerospace and other industries. The acquisition of ND Industries is expected to accelerate the realization of our top growth priorities, consistent with our strategy to proactively drive capital allocation to the highest margin, highest growth market segments within the functional coatings, adhesives, sealants and elastomer industry. The acquisition fair value measurement was final as of *March 1, 2025*. ND Industries is included in our Engineering Adhesives operating segment.

The following table summarizes the fair value measurement of the assets acquired and liabilities assumed as of the date of acquisition:

------

---

| | |
|:---|:---|
|  | ***Amounts*** |
| Current assets | $17085 |
| Property, plant and equipment | 26044 |
| Goodwill | 81268 |
| Other intangibles |  |
| Customer relationships | 110100 |
| Trademarks/trade names | 8700 |
| Technology | 13600 |
| Other assets | 13 |
| Current liabilities | (2773) |
| Total | $254037 |

---

The expected useful lives of the acquired intangible assets are 15 years for technology, 13 years for customer relationships and ten years for trademarks and tradenames. Based on the fair value measurement of the assets acquired and liabilities assumed, we allocated $81,268 to goodwill for the expected synergies from combining ND Industries with our existing business. Such goodwill is deductible for tax purposes. The goodwill was assigned to our Engineering Adhesives operating segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All acquisitions, individually and in the aggregate, are *not* material and therefore pro forma financial information is *not* provided.

*Divestiture*

 *North America Flooring*

On *December 2, 2024,* we completed the sale of certain assets in our North American Flooring business, which was included in our Construction Adhesives segment for $75,727. The net book value of the assets sold was $77,242, which resulted in a $1,515 loss. The loss on sale is recorded in other income net, in the Consolidated Statements of Income for the *nine* months ended *August 30, 2025*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

[**Table of Contents**](#toc)

**Note *3:* Restructuring Actions**

During fiscal year *2023,* the Company approved restructuring plans (the "Plans") related to organizational changes and other actions to optimize operations and integrate acquired businesses. The Plans were implemented in the *second* quarter of fiscal year *2023* and are currently expected to be completed during fiscal year *2026.* In implementing the Plans, the Company currently expects to incur pre-tax costs of approximately $70,000 to $75,000 for severance and related employee costs globally, other restructuring costs related to the streamlining of processes and the payment of anticipated income taxes in certain jurisdictions related to the Plans.

The following table summarizes the pre-tax distribution of charges under these restructuring plans by income statement classification:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30, 2025*** | ***August 31, 2024*** | ***August 30, 2025*** | ***August 31, 2024*** |
| Cost of sales | $**2393** | $2119 | $**5328** | $6313 |
| Selling, general and administrative | **634** | 2632 | **3386** | 5076 |
|  | $**3027** | $4751 | $**8714** | $11389 |

---

The restructuring charges are all recorded in Corporate Unallocated for segment reporting purposes.

A summary of the restructuring liability is presented below:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Employee-Related*** | ***Asset-Related*** | ***Other*** | ***Total*** |
| Balance at December 2, 2023 | $11723 | $- | $- | $11723 |
| Expenses incurred | 13477 | 4673 | 3936 | 22086 |
| Non-cash charges |  | (4673) | (3925) | (8598) |
| Cash payments | (16427) |  | (11) | (16438) |
| Foreign currency translation | (343) |  |  | (343) |
| Balance at November 30, 2024 | $8430 | $- | $- | $8430 |
| Expenses incurred | **4192** | **1574** | **2948** | **8714** |
| Non-cash charges | **-** | **(1574)** | **(426)** | **(2000)** |
| Cash payments | **(10462)** | **-** | **(2522)** | **(12984)** |
| Foreign currency translation | **339** | **-** | **-** | **339** |
| Balance at August 30, 2025 | $**2499** | $**-** | $**-** | $**2499** |

---

Non-cash charges primarily include accelerated depreciation and impairment resulting from the cessation of use of certain long-lived assets and the recording of an inventory provision related to the discontinuance of certain products. Restructuring liabilities have been classified as a component of other accrued expenses on the Consolidated Balance Sheets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

[**Table of Contents**](#toc)

**Note *4:* Inventories**

The composition of inventories is as follows:

---

| | | |
|:---|:---|:---|
|  | ***August 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** |
| Raw materials | $**220399** | $215936 |
| Finished goods | **282557** | 251562 |
| Total inventories | $**502956** | $467498 |

---

**Note *5:* Goodwill and Other Intangible Assets**

The goodwill activity by reportable segment for the *nine* months ended *August 30, 2025* is presented below:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Hygiene, Health*** |  | ***Building*** |  |
|  | ***and Consumable*** | ***Engineering*** | ***Adhesive*** |  |
|  | ***Adhesives*** | ***Adhesives*** | ***Solutions*** | ***Total*** |
| Balance at November 30, 2024 | $**399513** | $**581344** | $**551364** | $**1532221** |
| Acquisitions | **90198** | **2572** | **(851**) | **91919** |
| Foreign currency translation effect | **30716** | **24427** | **2604** | **57747** |
| Balance at August 30, 2025 | $**520427** | $**608343** | $**553117** | $**1681887** |

---

As discussed in Note *14,* as of the beginning of fiscal year *2025,* we realigned our operating segment structure with the renamed Building Adhesive Solutions segment, which includes all of the former Construction Adhesives goodwill. A portion of the Engineering Adhesives goodwill was reclassified to the Building Adhesive Solutions segment based on the relative fair value approach.

Balances of amortizable identifiable intangible assets, excluding goodwill and other non-amortizable intangible assets, are as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***August 30, 2025*** | ***August 30, 2025*** | ***August 30, 2025*** | ***August 30, 2025*** | ***August 30, 2025*** |
|  | ***Purchased*** |  |  |  |  |
|  | ***Technology*** | ***Customer*** |  |  |  |
| **Amortizable Intangible Assets** | ***and Patents*** | ***Relationships*** | ***Trade Names*** | ***Other*** | ***Total*** |
| Original cost | $**225700** | $**1000997** | $**82194** | $**7930** | $**1316821** |
| Accumulated amortization | **(48520)** | **(400390)** | **(33171)** | **(5310)** | **(487391)** |
| Net identifiable intangibles | $**177180** | $**600607** | $**49023** | $**2620** | $**829430** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***November 30, 2024*** | ***November 30, 2024*** | ***November 30, 2024*** | ***November 30, 2024*** | ***November 30, 2024*** |
|  | ***Purchased*** |  |  |  |  |
|  | ***Technology*** | ***Customer*** |  |  |  |
| **Amortizable Intangible Assets** | ***and Patents*** | ***Relationships*** | ***Trade Names*** | ***Other*** | ***Total*** |
| Original cost | $145313 | $1063210 | $67280 | $10031 | $1285834 |
| Impairment | (343) | (5616) | (150) |  | (6109) |
| Accumulated amortization | (55398) | (418805) | (28745) | (7012) | (509960) |
| Net identifiable intangibles | $89572 | $638789 | $38385 | $3019 | $769765 |

---

Amortization expense with respect to amortizable intangible assets was $22,082 and $22,149 for the *three* months ended *August 30, 2025* and *August 31, 2024*, respectively, and was $64,525 and $61,723 for the *nine* months ended *August 30, 2025* and *August 31, 2024*, respectively.

Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets for the next *five* fiscal years is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***Remainder*** |  |  |  |  |  |
| Fiscal Year | ***2025*** | ***2026*** | ***2027*** | ***2028*** | ***2029*** | ***Thereafter*** |
| Amortization expense | $23632 | $105293 | $103909 | $105102 | $99473 | $392021 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

[**Table of Contents**](#toc)

The above amortization expense forecast is an estimate. Actual amounts *may* change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, potential impairment, accelerated amortization or other events.

Non-amortizable intangible assets as of *August 30, 2025* and *November 30, 2024* were $0 and $461, respectively, and relate to trademarks and trade names. The change in non-amortizable assets as of *August 30, 2025* compared to *November 30, 2024* was due to impairment.

**Note *6:* Long-Term Debt**

On *March 6, 2025,* we entered into a Refinancing Amendment (the "Refinancing Amendment"), which amended the Second Amended and Restated Credit Agreement dated as of *February 15, 2023,* as previously amended. Pursuant to the Refinancing Amendment under the Credit Agreement, the outstanding $986,545 principal amount of Term B loans (the "Amended TLB") were refinanced. Furthermore, the interest rate margins applicable to the Amended TLB were decreased by 25 basis points (0.25 percent per annum) to 175 basis points for SOFR loans and 75 basis points for prime rate loans. Interest on Term Loan B borrowings is payable at SOFR plus an interest rate spread of 175 basis points with a SOFR floor of 50 basis points (6.07 percent at *August 30, 2025*). The maturity date of *February 15, 2030* remains unchanged. The commitment fee rates and interest rates applicable to the revolving credit facility and the Term Loan A facility remain unchanged.

**Note *7:* Components of Net Periodic Benefit related to Pension and Other Postretirement Benefit Plans**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***Three Months Ended August 30, 2025 and August 31, 2024*** | ***Three Months Ended August 30, 2025 and August 31, 2024*** | ***Three Months Ended August 30, 2025 and August 31, 2024*** | ***Three Months Ended August 30, 2025 and August 31, 2024*** | ***Three Months Ended August 30, 2025 and August 31, 2024*** | ***Three Months Ended August 30, 2025 and August 31, 2024*** |
|  |  |  |  |  | ***Other*** | ***Other*** |
|  | ***Pension Benefits*** | ***Pension Benefits*** | ***Pension Benefits*** | ***Pension Benefits*** | ***Postretirement*** | ***Postretirement*** |
|  | ***U.S. Plans*** | ***U.S. Plans*** | ***Non-U.S. Plans*** | ***Non-U.S. Plans*** | ***Benefits*** | ***Benefits*** |
| <u>Net periodic (benefit) cost:</u> | ***2025*** | ***2024*** | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Service cost | $**-** | $- | $**408** | $350 | $**-** | $- |
| Interest cost | **3242** | 3464 | **860** | 1575 | **249** | 291 |
| Expected return on assets | **(5717)** | (6555) | **(1094)** | (1643) | **(3484)** | (2727) |
| Amortization: |  |  |  |  |  |  |
| Prior service cost | **-** |  | **14** | 16 | **-** |  |
| Actuarial loss (gain) | **1953** | 1159 | **119** | 516 | **(2277**) |  |
| Net periodic (benefit) cost | $**(522)** | $(1932) | $**307** | $814 | $**(5512)** | $(2436) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***Nine Months Ended August 30, 2025 and August 31, 2024*** | ***Nine Months Ended August 30, 2025 and August 31, 2024*** | ***Nine Months Ended August 30, 2025 and August 31, 2024*** | ***Nine Months Ended August 30, 2025 and August 31, 2024*** | ***Nine Months Ended August 30, 2025 and August 31, 2024*** | ***Nine Months Ended August 30, 2025 and August 31, 2024*** |
|  |  |  |  |  | ***Other*** | ***Other*** |
|  | ***Pension Benefits*** | ***Pension Benefits*** | ***Pension Benefits*** | ***Pension Benefits*** | ***Postretirement*** | ***Postretirement*** |
|  | ***U.S. Plans*** | ***U.S. Plans*** | ***Non-U.S. Plans*** | ***Non-U.S. Plans*** | ***Benefits*** | ***Benefits*** |
| <u>Net periodic (benefit) cost:</u> | ***2025*** | ***2024*** | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Service cost | $**-** | $- | $**1161** | $1046 | $**-** | $- |
| Interest cost | **9726** | 10391 | **3797** | 4705 | **747** | 875 |
| Expected return on assets | **(17151)** | (19666) | **(4403)** | (4908) | **(10452)** | (8182) |
| Amortization: |  |  |  |  |  |  |
| Prior service cost | **-** |  | **70** | 48 | **-** |  |
| Actuarial loss (gain) | **5859** | 3478 | **1084** | 1540 | **(6831**) |  |
| Net periodic (benefit) cost | $**(1566)** | $(5797) | $**1709** | $2431 | $**(16536)** | $(7307) |

---

Service cost is included with employee compensation cost in cost of sales and selling, general and administrative expenses in the Consolidated Statements of Income. The components of our net periodic defined benefit pension and postretirement benefit costs other than service cost are presented in other income, net in the Consolidated Statements of Income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

[**Table of Contents**](#toc)

**Note *8:* Accumulated Other Comprehensive Income (Loss)**

The following table provides details of total comprehensive income (loss):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 31, 2024*** | ***Three Months Ended August 31, 2024*** | ***Three Months Ended August 31, 2024*** | ***Three Months Ended August 31, 2024*** |
|  |  |  |  | ***Non-*** |  |  |  | ***Non-*** |
|  |  |  |  | ***controlling*** |  |  |  | ***controlling*** |
|  | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***Interest*** | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***Interest*** |
|  | ***Pre-tax*** | ***Tax*** | ***Net*** | ***Net*** | ***Pre-tax*** | ***Tax*** | ***Net*** | ***Net*** |
| Net income attributable to H.B. Fuller and non-controlling interest |  |  | $**67160** | $**73** |  |  | $55361 | $(22) |
| Foreign currency translation¹ | $**36993** | $***-*** | **36993** | **(31)** | $33324 | $*-* | 33324 | 31 |
| Defined benefit pension plans adjustment² | **218** | **(60)** | **158** | ***-*** | 1689 | (419) | 1270 | *-* |
| Interest rate swaps³ | **(4424**) | **1077** | **(3347**) | ***-*** | (34068) | 8324 | (25744) | *-* |
| Net investment hedges³ | **(19822**) | **4824** | **(14998**) | ***-*** | (10892) | 2661 | (8231) | ***-*** |
| Other comprehensive income (loss) | $**12965** | $**5841** | $**18806** | $**(31)** | $(9947) | $10566 | $619 | $31 |
| Comprehensive income |  |  | $**85966** | $**42** |  |  | $55980 | $9 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 31, 2024*** | ***Nine Months Ended August 31, 2024*** | ***Nine Months Ended August 31, 2024*** | ***Nine Months Ended August 31, 2024*** |
|  |  |  |  | ***Non-*** |  |  |  | ***Non-*** |
|  |  |  |  | ***controlling*** |  |  |  | ***controlling*** |
|  | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***Interest*** | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***H.B. Fuller Stockholders*** | ***Interest*** |
|  | ***Pretax*** | ***Tax*** | ***Net*** | ***Net*** | ***Pretax*** | ***Tax*** | ***Net*** | ***Net*** |
| Net income attributable to H.B. Fuller and non-controlling interest |  |  | $**122236** | $**106** |  |  | $137615 | $32 |
| Foreign currency translation¹ | $**139592** | $***-*** | **139592** | **34** | $(12922) | $*-* | (12922) | (10) |
| Defined benefit pension plans adjustment² | **591** | **(162)** | **429** | *-* | 5065 | (1257) | 3808 | *-* |
| Interest rate swap³ | **(9146)** | **2226** | **(6920)** | *-* | (23851) | 5838 | (18013) | *-* |
| Net investment hedges³ | **(70646)** | **17193** | **(53453)** | ***-*** | (5704) | 1386 | (4318) | ***-*** |
| Other comprehensive income (loss) | $**60391** | $**19257** | $**79648** | $**34** | $(37412) | $5967 | $(31445) | $(10) |
| Comprehensive income |  |  | $**201884** | $**140** |  |  | $106170 | $22 |

---

<sup>*1*</sup> Income taxes are *not* provided for foreign currency translation relating to indefinite investments in international subsidiaries.

<sup>*2*</sup> Amounts reclassified from accumulated other comprehensive loss into earnings as part of net periodic cost related to pension and other postretirement benefit plans is reported in cost of sales and other income, net.

<sup>*3*</sup> Amounts reclassified from accumulated other comprehensive loss into earnings is reported in other income, net.

The components of accumulated other comprehensive loss are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | ***August 30, 2025*** | ***August 30, 2025*** | ***August 30, 2025*** |
|  |  |  | ***Non-*** |
|  |  | ***H.B. Fuller*** | ***controlling*** |
|  | ***Total*** | ***Stockholders*** | ***Interest*** |
| Foreign currency translation adjustment | $**(182626)** | $**(182206)** | $**(420)** |
| Defined benefit pension plans adjustment, net of taxes of $54,382 | **(88602)** | **(88602)** | **-** |
| Interest rate swap, net of taxes of $4,395 | **(13664**) | **(13664**) | **-** |
| Net investment hedges, net of taxes of $29,249 | **(90934)** | **(90934)** | **-** |
| Reclassification of AOCI tax effects | **(18341)** | **(18341)** | **-** |
| Accumulated other comprehensive loss | $**(394167)** | $**(393747)** | $**(420)** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | ***November 30, 2024*** | ***November 30, 2024*** | ***November 30, 2024*** |
|  |  |  | ***Non-*** |
|  |  | ***H.B. Fuller*** | ***controlling*** |
|  | ***Total*** | ***Stockholders*** | ***Interest*** |
| Foreign currency translation adjustment | $(322184) | $(321798) | $(386) |
| Defined benefit pension plans adjustment, net of taxes of $54,545 | (89031) | (89031) |  |
| Interest rate swap, net of taxes of $2,169 | (6744) | (6744) |  |
| Net investment hedges, net of taxes of $12,056 | (37481) | (37481) |  |
| Reclassification of AOCI tax effects | (18341) | (18341) |  |
| Accumulated other comprehensive loss | $(473781) | $(473395) | $(386) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

[**Table of Contents**](#toc)

**Note *9:* Income Taxes**

Income tax expense for the *three* and *nine* months ended *August 30, 2025* includes $3,742 of discrete tax benefit and $11,210 of discrete tax expense, respectively. The discrete tax benefit for the *three* months ended *August 30, 2025* relates to various U.S. and foreign tax matters. The discrete tax expense for the *nine* months ended *August 30, 2025* relates to the impact of withholding tax recorded on earnings that are *no* longer permanently reinvested, offset by various U.S. and foreign tax matters. Excluding the discrete tax benefit and expense, the overall effective tax rate was 24.4 percent and 25.2 percent for the *three* and *nine* months ended *August 30, 2025*, respectively.

Income tax expense for the *three* and *nine* months ended *August 31, 2024* includes $2,937 and $4,147 of discrete tax benefit, respectively, relating to an excess tax benefit on U.S. stock compensation, as well as other various U.S. and foreign tax matters. Excluding the discrete tax benefit, the overall effective tax rate was 29.3 percent and 28.7 percent for the *three* and *nine* months ended *August 31, 2024*, respectively.

As of *August 30, 2025*, we had a liability of $18,012 recorded for gross unrecognized tax benefits (excluding interest) compared to $15,590 as of *November 30, 2024*. As of *August 30, 2025* and *November 30, 2024*, we had accrued $3,495 and $4,558 of gross interest relating to unrecognized tax benefits, respectively.

**Note *10:* Earnings Per Share**

A reconciliation of the common share components for the basic and diluted earnings per share calculations is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30,*** | ***August 31,*** | ***August 30,*** | ***August 31,*** |
| (Shares in thousands) | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Weighted-average common shares - basic | **54428** | 54975 | **54623** | 54874 |
| Equivalent shares from share-based compensations plans | **734** | 1675 | **758** | 1746 |
| Weighted-average common and common equivalent shares diluted | **55162** | 56650 | **55381** | 56620 |

---

Basic earnings per share is calculated by dividing net income attributable to H.B. Fuller by the weighted-average number of common shares outstanding during the applicable period. Diluted earnings per share is based upon the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to share-based compensation awards. We use the treasury stock method to calculate the effect of outstanding shares, which computes total employee proceeds as the sum of (a) the amount the employee must pay upon exercise of the award and (b) the amount of unearned share-based compensation costs attributed to future services. Share-based compensation awards for which total employee proceeds exceed the average market price over the applicable period have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share.

Share-based compensation awards of 1,935,970 and 517,442 shares for the *three* months ended *August 30, 2025* and *August 31, 2024*, respectively, were excluded from diluted earnings per share calculations because they were antidilutive. Share-based compensation awards of 2,132,875 and 957,127 shares for the *nine* months ended *August 30, 2025* and *August 31, 2024*, respectively, were excluded from diluted earnings per share calculations because they were antidilutive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

[**Table of Contents**](#toc)

**Note *11:* Financial Instruments**

*Overview*

As a result of being a global enterprise, foreign currency exchange rates and fluctuations in those rates *may* affect the Company's net investment in foreign subsidiaries and our earnings, cash flows and financial position are exposed to foreign currency risk from foreign currency denominated receivables and payables.

We use foreign currency forward contracts, cross-currency swaps, interest rate swaps and net investment hedges to manage risks associated with foreign currency exchange rates and interest rates. We do *not* hold derivative financial instruments of a speculative nature or for trading purposes. We record derivatives as assets and liabilities on the balance sheet at fair value. Changes in fair value are recognized immediately in earnings unless the derivative qualifies and is designated as a hedge. Cash flows from derivatives are classified in the Consolidated Statement of Cash Flows in the same category as the cash flows from the items subject to designated hedge or undesignated (economic) hedge relationships. We evaluate hedge effectiveness at inception and on an ongoing basis. If a derivative is *no* longer expected to be effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is recorded in earnings.

We are exposed to credit risk in the event of nonperformance of counterparties for foreign currency forward exchange contracts and interest rate swap agreements. We select investment-grade multinational banks and financial institutions as counterparties for derivative transactions and monitor the credit quality of each of these banks on a periodic basis as warranted. We do *not* anticipate nonperformance by any of these counterparties, and valuation allowances, if any, are de minimis.

*Cash Flow Hedges*

On *January 12, 2023,* we entered into an interest rate swap agreement to convert $400,000 of our variable rate *1*-month LIBOR debt to a fixed rate of 3.6895 percent that matures on *January 12, 2028.* On *February 28, 2023,* after refinancing our debt, we amended the interest rate swap agreement to our *1*-month SOFR rate debt to a fixed rate of 3.7260 in accordance with the practical expedients included in ASC *848,* *Reference Rate Reform*. The combined fair value of the interest rate swap was a liability of $3,756 at *August 30, 2025* and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for this interest rate swap. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swap.

On *March 16, 2023,* we entered into an interest rate swap agreement to convert $300,000 of our *1*-month SOFR debt to a fixed rate of 3.7210 percent that matures on *February 15, 2028.* The combined fair value of the interest rate swap was a liability of $3,067 at *August 30, 2025* and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for this interest rate swap. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swaps.

On *March 16, 2023,* we entered into an interest rate swap agreement to convert $100,000 of our *1*-month SOFR debt to a fixed rate of 3.8990 percent that matures on *February 15, 2028.* The combined fair value of the interest rate swap was a liability of $1,407 at *August 30, 2025* and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for these interest rate swaps. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swaps.

The amounts of pretax losses recognized in Comprehensive Income related to derivative instruments designated as cash flow hedges are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30, 2025*** | ***August 31, 2024*** | ***August 30, 2025*** | ***August 31, 2024*** |
| Interest rate swap contracts | **(4424)** | (34068) | **(9146**) | (23851) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

[**Table of Contents**](#toc)

*Fair Value Hedges*

On *February 12, 2021,* we entered into interest rate swap agreements to convert our $300,000 Public Notes that were issued on *October 20, 2020* to a variable interest rate of *1*-month LIBOR plus 3.28 percent. On *June 30, 2023, 1*-month LIBOR rates ceased to exist and the IBOR Fallbacks Protocol published by the International Swaps and Derivatives Association ("ISDA") took effect as outlined in the interest rate swap agreement. As a result, the interest rate swap agreement was converted to Overnight SOFR plus 3.28 percent. We applied the practical expedients included in ASC *848, Reference Rate Reform*. These interest rate swap agreements mature on *October 15, 2028.* The combined fair value of the interest rate swaps was a liability of $22,571 at *August 30, 2025*, and was included in other liabilities in the Consolidated Balance Sheets. The swaps were designated for hedge accounting treatment as fair value hedges. We apply the short cut method and assume hedge effectiveness. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our $300,000 fixed rate Public Notes are compared with the change in the fair value of the swaps.

*Net Investment Hedges*

On *October 17, 2022,* we entered into a float-to-float cross-currency interest rate swap agreement with a notional amount of €307,173 maturing in *October 2028.* On *October 20, 2022,* we entered into fixed-to-fixed cross-currency interest rate swap agreements for a total notional amount of €300,000 with tranches maturing in *August 2025, August 2026* and *February 2027.* On *July 18, 2025,* we amended the agreement for the two tranches of the fixed-to-fixed cross-currency interest rate swap, of €50,000 each, that matured in *August 2025* to a maturity date of *February 2027.* On *June 30, 2023, 1*-month LIBOR rates ceased to exist and the IBOR Fallbacks Protocol published by the International Swaps and Derivatives Association (ISDA) took effect as outlined in the interest rate swap agreement. As a result, the *1*-month LIBOR leg of the float-to-float agreement was converted to Overnight SOFR plus 3.28 percent. On *July 17, 2023,* we amended the *1*-month EURIBOR leg of the float-to-float agreement to Overnight ESTR plus 3.2195 percent. We applied the practical expedients included in ASC *848, Reference Rate Reform*. As of *August 30, 2025*, the combined fair value of the swaps was a liability of $120,188 and was included in other liabilities in the Consolidated Balance Sheets. The cross-currency interest rate swaps hedge a portion of the Company's investment in Euro denominated foreign subsidiaries.

The swaps are designated as net investment hedges for accounting treatment. The net gains or losses attributable to changes in spot exchange rates are recorded in the cumulative translation adjustment within other comprehensive income. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The amount in accumulated other comprehensive income (loss) related to net investment hedge cross-currency swaps was a loss of $90,934 as of *August 30, 2025*. The amounts of pretax loss recognized in comprehensive income related to the net investment hedge was $19,822 for the *three* months ended *August 30, 2025*. As of *August 30, 2025*, we reclassified $174 of losses into earnings from net investment hedges and we expect to reclassify $353 of losses into earnings within the next *twelve* months. This is related to the portion excluded from the assessment of hedge effectiveness for the net investment hedges in the amount of $706.

*Derivatives *Not* Designated as Hedging Instruments*

We use foreign currency forward contracts to offset our exposure to the change in value of certain foreign currency denominated assets and liabilities held at foreign subsidiaries that are remeasured at the end of each period. Although the contracts are effective economic hedges, they are *not* designated as accounting hedges. Foreign currency forward contracts are recorded as assets and liabilities on the balance sheet at fair value. Changes in the value of these derivatives are recognized immediately in earnings, thereby offsetting the current earnings effect of the related foreign currency denominated assets and liabilities. See Note *12* for the fair value amounts of these derivative instruments.

As of *August 30, 2025*, we had forward foreign currency contracts maturing between *September 2, 2025* and *February 4, 2026.* The mark-to-market effect associated with these contracts was largely offset by the underlying transaction gains and losses resulting from the foreign currency exposures for which these contracts relate.

The amounts of pretax gains recognized in other income, net related to derivative instruments *not* designated as hedging instruments for the *nine* months ended *August 30, 2025* and *August 31, 2024* were $2,989 and 1,524, respectively.

Concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of entities in the customer base and their dispersion across many different industries and countries. As of *August 30, 2025*, there were *no* significant concentrations of credit risk.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

[**Table of Contents**](#toc)

**Note *12:* Fair Value Measurements** 

*Overview*

Estimates of fair value for financial assets and liabilities are based on the framework established in the accounting guidance for fair value measurements. The framework defines fair value, provides guidance for measuring fair value and requires certain disclosures. The framework discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The framework utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into *three* broad levels. The following is a brief description of those *three* levels:

● Level *1:* Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

● Level *2:* Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are *not* active.

● Level *3:* Unobservable inputs that reflect management's assumptions, and include situations where there is little, if any, market activity for the asset or liability.

*Balances Measured at Fair Value on a Recurring Basis*

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis as of *August 30, 2025* and *November 30, 2024*, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***August 30,*** | ***Fair Value Measurements Using:*** | ***Fair Value Measurements Using:*** | ***Fair Value Measurements Using:*** |
| Description | ***2025*** | ***Level 1*** | ***Level 2*** | ***Level 3*** |
| Assets: |  |  |  |  |
| Marketable securities | $**4199** | $**4199** | $***-*** | $***-*** |
| Foreign exchange contract assets | **3810** | ***-*** | **3810** | ***-*** |
| Liabilities: |  |  |  |  |
| Foreign exchange contract liabilities | $**821** | $***-*** | $**821** | $***-*** |
| Interest rate swaps, cash flow hedge liabilities | **8230** |  | **8230** |  |
| Interest rate swaps, fair value hedge liabilities | **22571** | **-** | **22571** | **-** |
| Net investment hedge liabilities | **120188** | **-** | **120188** | **-** |
| Holdback liability | **33570** | **-** | **-** | **33570** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***November 30,*** | ***Fair Value Measurements Using:*** | ***Fair Value Measurements Using:*** | ***Fair Value Measurements Using:*** |
| Description | ***2024*** | ***Level 1*** | ***Level 2*** | ***Level 3*** |
| Assets: |  |  |  |  |
| Marketable securities | $8584 | $8584 | $*-* | $*-* |
| Foreign exchange contract assets | 2147 | *-* | 2147 | *-* |
| &nbsp;&nbsp;&nbsp; Interest rate swaps, cash flow hedge assets | 1781 |  | 1781 |  |
| Liabilities: |  |  |  |  |
| Foreign exchange contract liabilities | $7074 | $*-* | $7074 | $*-* |
| Interest rate swaps, cash flow hedge liabilities | 265 |  | 265 |  |
| Interest rate swaps, fair value hedge liabilities | 32775 |  | 32775 |  |
| Net investment hedge liabilities | 51871 |  | 51871 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *20*

------

[**Table of Contents**](#toc)

The fair value of the holdback liability related to the acquisition of GEM and Medifill, based on a discounted cash flow model, was $33,570 as of *August 30, 2025*. Adjustments to the fair value of the holdback are recorded to interest expense in the Statement of Income. See Note *2* for further discussion regarding our acquisitions. The following table provides details of this Level *3* liability.

---

| | |
|:---|:---|
|  | ***Amounts*** |
| Balance at November 30, 2024 | $- |
| Initial valuation of holdback liability | 28922 |
| Interest | 641 |
| Foreign currency translation adjustment | 4007 |
| Balance at August 30, 2025 | $33570 |

---

*Balances Measured at Fair Value on a Nonrecurring Basis*

We measure certain assets and liabilities at fair value on a nonrecurring basis. These assets include intangible assets acquired in an acquisition. The identified intangible assets of customer relationships, technology and tradenames acquired in connection with our acquisitions were measured using unobservable (Level *3*) inputs. The fair value of the intangible assets was calculated using either the income or cost approach. Significant inputs include estimated revenue growth rates, gross margins, operating expenses, attrition rate, royalty rate and discount rate.

See Note *2* for further discussion regarding our acquisitions.

*Balances Disclosed at Fair Value*

Long-term debt had an estimated fair value of $2,082,934 and $2,015,468 as of *August 30, 2025* and *November 30, 2024*, respectively. The fair value of long-term debt is based on quoted market prices for the same or similar issues or on the current rates offered for debt of similar maturities. The estimated fair value of these long-term obligations is *not* necessarily indicative of the amount that would be realized in a current market exchange.

**Note *13:* Commitments and Contingencies**

*Environmental Matters*

We are involved in environmental investigations, clean-up activities and administrative proceedings related to environmental compliance matters at former and current operating facilities. We have also been identified as a potentially responsible party ("PRP") under the Comprehensive Environmental Response, Compensation and Liability Act ("CERCLA") and/or similar state laws that impose liability for costs relating to the clean-up of contamination resulting from past spills, disposal or other release of hazardous substances associated with landfills and/or hazardous waste sites. As a PRP, we *may* be required to pay a share of the costs of investigation and clean-up of these sites. We are subject to similar laws in some of the countries where current and former facilities are located. Our environmental, health and safety department monitors compliance with applicable laws on a global basis. To the extent we can reasonably estimate the amount of our probable liabilities for environmental matters, we establish an undiscounted financial provision. We recorded liabilities of $2,818 and $3,445 as of *August 30, 2025* and *November 30, 2024*, respectively, for probable and reasonably estimable environmental remediation costs. Of the amount reserved, $508 and $1,055 as of *August 30, 2025* and *November 30, 2024*, respectively, is attributable to a facility we own in Simpsonville, South Carolina that is a designated site under CERCLA.

While uncertainties exist with respect to the amounts and timing of the ultimate environmental liabilities, based on currently available information, we have concluded that these matters, individually or in the aggregate, will *not* have a material adverse effect on our results of operations, financial condition or cash flow.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *21*

------

[**Table of Contents**](#toc)

*Other Legal Proceedings*

From time to time and in the ordinary course of business, we are a party to, or a target of, lawsuits, claims, investigations and proceedings, including product liability, personal injury, contract, patent and intellectual property, environmental, health and safety, tax and employment matters. While we are unable to predict the outcome of these matters, we have concluded, based upon currently available information, that the ultimate resolution of any pending matter, individually or in the aggregate, including the asbestos litigation described in the following paragraphs, will *not* have a material adverse effect on our results of operations, financial condition or cash flow.

We have been named as a defendant in lawsuits in which plaintiffs have alleged injury due to products containing asbestos manufactured more than *35* years ago. The plaintiffs generally bring these lawsuits against multiple defendants and seek damages (both actual and punitive) in very large amounts. In many cases, plaintiffs are unable to demonstrate that they have suffered any compensable injuries or that the injuries suffered were the result of exposure to products manufactured by us. We are typically dismissed as a defendant in such cases without payment. If the plaintiff presents evidence indicating that compensable injury occurred as a result of exposure to our products, the case is generally settled for an amount that reflects the seriousness of the injury, the length, intensity and character of exposure to products containing asbestos, the number and solvency of other defendants in the case, and the jurisdiction in which the case has been brought.

A significant portion of the defense costs and settlements in asbestos-related litigation is paid by *third* parties, including indemnification pursuant to the provisions of a *1976* agreement under which we acquired a business from a *third* party. Currently, this *third* party is defending and paying settlement amounts, under a reservation of rights, in most of the asbestos cases tendered to the *third* party.

In addition to the indemnification arrangements with *third* parties, we have insurance policies that generally provide coverage for asbestos liabilities, including defense costs. Historically, insurers have paid a significant portion of our defense costs and settlements in asbestos-related litigation. However, certain of our insurers are insolvent. We have entered into cost-sharing agreements with our insurers that provide for the allocation of defense costs and settlements and judgments in asbestos-related lawsuits. These agreements require, among other things, that we fund a share of settlements and judgments allocable to years in which the responsible insurer is insolvent.

A summary of the number of and settlement amounts for asbestos-related lawsuits and claims is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | ***Nine Months Ended*** | ***Nine Months Ended*** | ***3 Years Ended*** |
|  | ***August 30, 2025*** | ***August 31, 2024*** | ***November 30, 2024*** |
| Lawsuits and claims settled | **7** | 9 | 25 |
| Settlement amounts | $**369** | $1208 | $5704 |
| Insurance payments received or expected to be received | $**252** | $844 | $3418 |

---

We do *not* believe that it would be meaningful to disclose the aggregate number of asbestos-related lawsuits filed against us because relatively few of these lawsuits are known to involve exposure to asbestos-containing products that we manufactured. Rather, we believe it is more meaningful to disclose the number of lawsuits that are settled and result in a payment to the plaintiff. To the extent we can reasonably estimate the amount of our probable liabilities for pending asbestos-related claims, we establish a financial provision and a corresponding receivable for insurance recoveries.

In *February 2024,* the named plaintiffs in *Rouse et al. v. H.B. Fuller Company et al.* filed a *third* amended complaint in their lawsuit against the Company and *one* of its subsidiaries, which was initiated in *September 2022.* The suit is pending in the federal District of Minnesota and seeks damages arising from property damage attributed to alleged defects in grout sold by the Company or its affiliates. The named plaintiffs seek to represent a class but have *not* yet moved for class certification. The court has ordered the parties and their insurers to attend a meditation session on or around *October 21* and *22, 2025.* The Company intends to vigorously defend itself against the claims outlined in this lawsuit. As of *August 30, 2025*, we are unable to estimate any possible loss or range of possible losses and have *not* recorded a loss contingency for this matter.

Based on currently available information, we have concluded that the resolution of any pending matter, including asbestos-related litigation, individually or in the aggregate, will *not* have a material adverse effect on our results of operations, financial condition or cash flow.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *22*

------

[**Table of Contents**](#toc)

**Note *14:* Share Repurchase Program**

On *April 22, 2022,* the Board of Directors authorized a share repurchase program of up to $300,000 of our outstanding common shares for a period of up to five years. Under the program, we are authorized to repurchase shares for cash on the open market, from time to time, in privately negotiated transactions or block transactions, or through an accelerated repurchase agreement. The timing of such repurchases is dependent on price, market conditions and applicable regulatory requirements. Upon repurchasing shares, we reduce our common stock for the par value of the shares with the excess being applied against additional paid-in capital.

During the *third* quarter of *2025*, there were no shares repurchased under this program. During the *nine* months ended *August 30, 2025*, we repurchased shares under this program with an aggregate value of $56,930. Of this amount, $978 reduced common stock and $55,953 reduced additional paid-in capital.

During the *third* quarter of *2024*, we repurchased shares under this program with an aggregate value of $17,549. Of this amount, $225 reduced common stock and $17,324 reduced additional paid-in capital. During the *nine* months ended *August 31, 2024*, we repurchased shares under this program with an aggregate value of $31,811. Of this amount, $407 reduced common stock and $31,404 reduced additional paid-in capital.

**Note *15:* Segments**

We are required to report segment information in the same way that we internally organize our business for assessing performance and making decisions regarding allocation of resources. Revenue and operating income of each of our segments are regularly reviewed by our chief operating decision maker to make decisions about resources to be allocated to the segments and assess their performance. Segment operating income is identified as gross profit less SG&A expenses. Corporate expenses, other than those included in Corporate Unallocated, are allocated to each operating segment. Consistent with our internal management reporting, Corporate Unallocated amounts include business acquisition and integration costs, organizational restructuring charges and project costs associated with implementing a global Enterprise Resource Planning ("ERP") system that we refer to as Project ONE. Corporate assets are *not* allocated to the operating segments. Inter-segment revenues are recorded at cost plus a markup for administrative costs.

As of *November 30, 2024,* our three operating segments consisted of Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. As of the beginning of fiscal *2025,* we reorganized our operating segments by selling our North American Flooring business ("NA Flooring"), previously part of the Construction Adhesives operating segment, and combining our Insulated Glass, Woodworking and Composite businesses, previously part of the Engineering Adhesives operating segment, with Construction Adhesives Roofing and Building Envelope and Infrastructure businesses to form the newly named Building Adhesive Solutions operating segment. All financial results related to NA Flooring have been moved to our Corporate Unallocated segment. Prior period segment information has been recast retrospectively to reflect the realignment. Operating results of each of these segments are regularly reviewed by our chief operating decision maker to make decisions about resources to be allocated to the segments and assess their performance.

The table below provides certain information regarding net revenue and operating income (loss) for each of our operating segments.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Three Months Ended*** | ***Three Months Ended*** |
|  | ***August 30, 2025*** | ***August 30, 2025*** | ***August 31, 2024*** | ***August 31, 2024*** |
|  | ***Net*** | ***Operating*** | ***Net*** | ***Operating*** |
|  | ***Revenue*** | ***Income (Loss)*** | ***Revenue*** | ***Income (Loss)*** |
| Hygiene, Health and Consumable Adhesives | $**386068** | $**46491** | $389980 | $48677 |
| Engineering Adhesives | **272297** | **46852** | 260038 | 40087 |
| Building Adhesive Solutions | **233678** | **25859** | 228408 | 25976 |
| Total segment | $**892043** | $**119202** | $878426 | $114740 |
| Corporate Unallocated | **-** | **(9062)** | 39501 | (10399) |
| Total | $**892043** | $**110140** | $917927 | $104341 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Nine Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30, 2025*** | ***August 30, 2025*** | ***August 31, 2024*** | ***August 31, 2024*** |
|  | ***Net*** | ***Operating*** | ***Net*** | ***Operating*** |
|  | ***Revenue*** | ***Income (Loss)*** | ***Revenue*** | ***Income (Loss)*** |
| Hygiene, Health and Consumable Adhesives | $**1151768** | $**119840** | $1151371 | $145910 |
| Engineering Adhesives | **785474** | **121880** | 743726 | 104894 |
| Building Adhesive Solutions | **641559** | **54550** | 630558 | 55102 |
| Total segment | $**2578801** | $**296270** | $2525655 | $305906 |
| Corporate Unallocated | **-** | **(39639)** | 119797 | (34093) |
| Total | $**2578801** | $**256631** | $2645452 | $271813 |

---

The table below provides a reconciliation of operating income to income before income taxes and income from equity method investments:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***August 30,*** | ***August 31,*** | ***August 30,*** | ***August 31,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Operating income | $**110140** | $104341 | $**256631** | $271813 |
| Other income, net | **5308** | 2148 | **15655** | 7282 |
| Interest expense | **(33630)** | (35288) | **(100536)** | (99504) |
| Interest income | **1110** | 1092 | **3064** | 3597 |
| Income before income taxes and income from equity method investments | $**82928** | $72293 | $**174814** | $183188 |

---

The table below provides total assets as of *November 30, 2024,* restated for our new operating segments:

---

| | |
|:---|:---|
|  | **November 30,** |
|  | **2024** |
| Hygiene, Health and Consumable Adhesives | $1610902 |
| Engineering Adhesives | 1533675 |
| Building Adhesive Solutions | 1239527 |
| Corporate | 549140 |
| Total | $4933244 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *23*

------

[**Table of Contents**](#toc)

We view the following disaggregation of net revenue by geographic region as useful to understanding the composition of revenue recognized during the respective reporting periods:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 30, 2025*** | ***Three Months Ended August 30, 2025*** |
|  | ***Hygiene, Health*** |  | ***Building*** |  |  |
|  | ***and Consumable*** | ***Engineering*** | ***Adhesive*** | ***Corporate*** |  |
|  | ***Adhesives*** | ***Adhesives*** | ***Solutions*** | ***Unallocated*** | ***Total*** |
| Americas | $**215634** | $**117894** | $**130236** | $**-** | $**463764** |
| EIMEA | **122251** | **59778** | **87934** | **-** | **269963** |
| Asia Pacific | **48183** | **94625** | **15508** | **-** | **158316** |
| Total | $**386068** | $**272297** | $**233678** | $**-** | $**892043** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Three Months Ended August 31, 2024*** | ***Three Months Ended August 31, 2024*** | ***Three Months Ended August 31, 2024*** | ***Three Months Ended August 31, 2024*** | ***Three Months Ended August 31, 2024*** |
|  | ***Hygiene, Health*** |  | ***Building*** |  |  |
|  | ***and Consumable*** | ***Engineering*** | ***Adhesive*** | ***Corporate*** |  |
|  | ***Adhesives*** | ***Adhesives*** | ***Solutions*** | ***Unallocated*** | ***Total*** |
| Americas | $223016 | $110163 | $128834 | $39501 | $501514 |
| EIMEA | 115740 | 57142 | 82759 |  | 255641 |
| Asia Pacific | 51224 | 92733 | 16815 |  | 160772 |
| Total | $389980 | $260038 | $228408 | $39501 | $917927 |

---

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 30, 2025*** | ***Nine Months Ended August 30, 2025*** |
|  | ***Hygiene, Health*** |  | ***Building*** |  |  |
|  | ***and Consumable*** | ***Engineering*** | ***Adhesive*** | ***Corporate*** |  |
|  | ***Adhesives*** | ***Adhesives*** | ***Solutions*** | ***Unallocated*** | ***Total*** |
| Americas | $**651007** | $**334265** | $**352396** | $**-** | $**1337668** |
| EIMEA | **351256** | **171594** | **245170** | **-** | **768020** |
| Asia Pacific | **149505** | **279615** | **43993** | **-** | **473113** |
| Total | $**1151768** | $**785474** | $**641559** | $**-** | $**2578801** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Nine Months Ended August 31, 2024*** | ***Nine Months Ended August 31, 2024*** | ***Nine Months Ended August 31, 2024*** | ***Nine Months Ended August 31, 2024*** | ***Nine Months Ended August 31, 2024*** |
|  | ***Hygiene, Health*** |  | ***Building*** |  |  |
|  | ***and Consumable*** | ***Engineering*** | ***Adhesive*** | ***Corporate*** |  |
|  | ***Adhesives*** | ***Adhesives*** | ***Solutions*** | ***Unallocated*** | ***Total*** |
| Americas | $668073 | $304809 | $338048 | $119797 | $1430727 |
| EIMEA | 331307 | 172029 | 245696 |  | 749032 |
| Asia Pacific | 151991 | 266888 | 46814 |  | 465693 |
| Total | $1151371 | $743726 | $630558 | $119797 | $2645452 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *24*

------

[**Table of Contents**](#toc)

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Overview**

The Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read in conjunction with the MD&A included in our Annual Report on Form 10-K for the year ended November 30, 2024, for important background information related to our business.

Net revenue in the third quarter of 2025 decreased 2.8 percent from the third quarter of 2024. The decrease was due to a 2.9 percent decrease in acquisitions/divestitures, and a 1.9 percent decrease due to sales volume, partially offset by a 1.0 percent increase due to positive currency effects compared to the third quarter of 2024 and a 1.0 percent increase due to pricing. The positive currency effect was primarily driven by a stronger Euro, British pound, and Egyptian pound, partially offset by a weaker Turkish lira compared to the U.S. dollar. Gross profit margin increased 200 basis points primarily due to the higher product pricing, lower distribution costs, and the impact of acquisitions/divestitures.

Net revenue in the first nine months of 2025 decreased 2.5 percent from the first nine months of 2024. The decrease was due to a 1.8 percent decrease in acquisitions/divestitures, a 1.1 percent decrease due to negative currency effects compared to the first nine months of 2024 and a 0.2 percent decrease due to sales volume, partially offset by a 0.6 increase due to pricing. The negative currency effect was primarily driven by a weaker Brazilian real, Egyptian pound, Mexican peso and Turkish lira, partially offset by a stronger Euro compared to the U.S. dollar. Gross profit margin increased 90 basis points due to higher pricing and the impact of acquisitions/divestitures.

Net income attributable to H.B. Fuller in the third quarter of 2025 was $67.2 million compared to $55.4 million in the third quarter of 2024. Diluted earnings per share for the third quarter of 2025 was $1.22 per share compared to $0.98 per share for the third quarter of 2024.

Net income attributable to H.B. Fuller in the first nine months of 2025 was $122.2 million compared to $137.6 million in the first nine months of 2024. Diluted earnings per share for the first nine months of 2025 was $2.21 per share compared to $2.43 per share for the first nine months of 2024.

**Restructuring Plans**

During the second and third quarters of 2023, the Company approved restructuring plans (the "Plans") related to organizational changes and other actions to optimize operations and integrate acquired businesses. In implementing the Plans, the Company currently expects to incur costs of approximately $70.0 million to $75.0 million ($47.8 million to $51.2 million after-tax), which include (i) cash expenditures of approximately $41.0 million to $42.0 million ($28.0 million to $28.7 million after tax) for severance and related employee costs globally and (ii) other restructuring costs related to the streamlining of processes and the payment of anticipated income taxes in certain jurisdictions related to the Plans. We have incurred costs of $69.7 million under the Plans as of August 30, 2025. The Plans were implemented in the second quarter of fiscal year 2023 and are currently expected to be completed during fiscal year 2026. The remaining restructuring costs will be spread across the next several fiscal quarters as the measures are implemented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25

------

[**Table of Contents**](#toc)

**Results of Operations**

**Net revenue:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Net revenue | $892.0 | $917.9 | (2.8)% | $2578.8 | $2645.5 | (2.5)% |

---

We review variances in net revenue in terms of changes related to sales volume and product pricing (referred to as organic revenue growth), business acquisitions and divestitures ("M&A") and changes in foreign currency exchange rates. The following table shows the net revenue variance analysis for the third quarter and first nine months of 2025 compared to the third quarter and first nine months of 2024:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Nine Months Ended** |
|  | **August 30, 2025 vs. August 31, 2024** | **August 30, 2025 vs. August 31, 2024** |
| Organic growth | (0.9)% | 0.4% |
| M&A | (2.9)% | (1.8)% |
| Currency | 1.0% | (1.1)% |
| Total | (2.8)% | (2.5)% |

---

Organic revenue decreased 0.9 percent in the third quarter of 2025 compared to the third quarter of 2024 driven by a 1.9 percent decrease in sales volume, partially offset by a 1.0 percent increase in product pricing. The 2.9 percent decrease from M&A was due to the sale of our North American Flooring business ("NA Flooring"), discussed further in Operating Segment Results below, net of acquisitions that occurred in the last twelve months. The positive 1.0 percent foreign currency impact was primarily driven by a stronger Euro, British pound, and Egyptian pound, partially offset by a weaker Turkish lira compared to the U.S. dollar.

Organic revenue increased 0.4 percent in the first nine months of 2025 compared to the first nine months of 2024 driven by a 0.6 percent increase in product pricing, partially offset by a 0.2 percent decrease in sales volume. The 1.8 percent decrease from M&A was due to the sale of NA Flooring, net of acquisitions that occurred in the last twelve months. The negative 1.1 percent foreign currency impact was primarily driven by a weaker Brazilian real, Egyptian pound, Mexican peso and Turkish lira, partially offset by a stronger Euro compared to the U.S. dollar.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26

------

[**Table of Contents**](#toc)

**Cost of sales:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Cost of sales | $606.9 | $642.2 | (5.5)% | $1780.2 | $1848.5 | (3.7)% |
| Percent of net revenue | 68.0% | 70.0% |  | 69.0% | 69.9% |  |

---

Cost of sales as a percentage of net revenue in the third quarter of 2025 compared to the third quarter of 2024 decreased 200 basis points. Raw material cost as a percentage of net revenue decreased 130 basis points in 2025 compared to 2024 primarily due to higher product pricing and the impact of acquisitions/divestitures. Other manufacturing costs as a percentage of net revenue decreased 70 basis points in 2025 compared to 2024 due to lower manufacturing and distribution costs, and the impact of acquisitions/divestitures.

Cost of sales as a percentage of net revenue in the first nine months of 2025 compared to the first nine months of 2024 decreased 90 basis points. Raw material cost as a percentage of net revenue decreased 50 basis points in 2025 compared to 2024. Other manufacturing costs as a percentage of net revenue decreased 40 basis points in 2025 compared to 2024.

**Gross profit:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Gross profit | $285.1 | $275.7 | 3.4% | $798.6 | $797.0 | 0.2% |
| Percent of net revenue | 32.0% | 30.0% |  | 31.0% | 30.1% |  |

---

Gross profit in the third quarter of 2025 increased 3.4 percent and gross profit margin increased 200 basis points compared to the third quarter of 2024. The increase in gross profit margin was due to due to higher product pricing and the impact of acquisitions/divestitures.

Gross profit in the first nine months of 2025 increased 0.2 percent and gross profit margin increased 90 basis points compared to the first nine months of 2024. The increase in gross profit margin was due to higher product pricing and the impact of acquisitions/divestitures.

**Selling, general and administrative (SG&A) expenses:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| SG&A | $175.0 | $171.4 | 2.1% | $541.9 | $525.2 | 3.2% |
| Percent of net revenue | 19.6% | 18.7% |  | 21.0% | 19.9% |  |

---

SG&A expenses for the third quarter of 2025 compared to the third quarter of 2024 increased 90 basis points as a percentage of net revenue. The increase was due to higher compensation costs and the impact of acquisitions/divestitures.

SG&A expenses for the first nine months of 2025 compared to the first nine months of 2024 increased 110 basis points as a percentage of net revenue. The increase was due to higher compensation costs and the impact of acquisitions/divestitures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

[**Table of Contents**](#toc)

**Other income, net:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Other income, net | $5.3 | $2.1 | 152.4% | $15.7 | $7.3 | 115.1% |

---

Other income, net in the third quarter of 2025 included $5.7 million of net defined benefit pension benefits and $0.1 million of other income, partially offset by a $0.5 million of currency transaction losses. Other income, net in the third quarter of 2024 included $4.0 million of net defined benefit pension benefits, and $0.3 million of currency transaction gains, partially offset by a $2.0 million loss on equity investment and $0.2 million of other expense.

Other income, net in the first nine months of 2025 included $17.1 million of net defined benefit pension benefits and $1.5 million of currency transaction gains, partially offset by a $1.5 million loss on the sale of our NA Flooring business and $1.4 million of other expense. Other income, net in the first nine months of 2024 included $11.9 million of net defined benefit pension benefits, partially offset by $2.0 million of currency transaction losses, a $2.0 million loss on equity investment and $0.6 million of other expense.

**Interest expense:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Interest expense | $33.6 | $35.3 | (4.8)% | $100.5 | $99.5 | 1.0% |

---

Interest expense in the third quarter of 2025 was $33.6 million compared to $35.3 million in the third quarter of 2024 due to lower interest rates partially offset by higher debt levels.

Interest expense in the first nine months of 2025 was $100.5 million compared to $99.5 million in the first nine months of 2024 due to higher debt levels.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28

------

[**Table of Contents**](#toc)

**Interest income:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Interest income | $1.1 | $1.1 | 0.0% | $3.1 | $3.6 | (13.9)% |

---

Interest income in the third quarter of 2025 and 2024 was $1.1 million and $1.1 million, respectively, consisting primarily of interest on cross-currency swap activity and other miscellaneous interest income.

Interest income in the first nine months of 2025 and 2024 was $3.1 million and $3.6 million, respectively, consisting primarily of interest on cross-currency swap activity and other miscellaneous interest income.

**Income taxes:** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Income taxes | $16.5 | $18.3 | (9.8)% | $55.2 | $48.5 | 13.8% |
| Effective tax rate | 19.9% | 25.3% |  | 31.6% | 26.5% |  |

---

Income tax expense of $16.5 million in the third quarter of 2025 includes $3.7 million of discrete tax benefit. Excluding the discrete tax benefit, the overall effective tax rate was 24.4 percent. The discrete tax benefit relates to various U.S. and foreign tax matters. Income tax expense of $18.3 million in the third quarter of 2024 includes $2.9 million of discrete tax benefit. Excluding the discrete tax benefit, the overall effective tax rate was 29.3 percent. The discrete tax benefit related to an excess tax benefit on U.S. stock compensation, as well as other various U.S. and foreign tax matters.

Income tax expense of $55.2 million in the first nine months of 2025 includes $11.2 million of discrete tax expense. Excluding the discrete tax expense, the overall effective tax rate was 25.2 percent. The discrete tax expense relates to the impact of withholding tax recorded on earnings that are no longer permanently reinvested, offset by various U.S. and foreign tax matters. Income tax expense of $48.5 million in the first nine months of 2024 includes $4.1 million of discrete tax benefit. Excluding the discrete tax benefit, the overall effective tax rate was 28.7 percent. The discrete tax benefit related to an excess tax benefit on U.S. stock compensation, as well as other various U.S. and foreign tax matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29

------

[**Table of Contents**](#toc)

**Income from equity method investments:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Income from equity method investments | $0.8 | $1.3 | (38.5)% | $2.7 | $3.0 | (10.0)% |

---

The income from equity method investments relates to our 50 percent ownership of the Sekisui-Fuller joint venture in Japan. The lower income for the third quarter of 2025 compared to the third quarter of 2024 is due to lower net income in our joint venture during the quarter compared to the prior year partially offset by the strengthening of the Japanese yen compared to the U.S. dollar.

The income from equity method investments relates to our 50 percent ownership of the Sekisui-Fuller joint venture in Japan. The lower income for the first nine months of 2025 compared to the first nine months of 2024 is due to lower net income in our joint venture compared to the prior year partially offset by the strengthening of the Japanese yen compared to the U.S. dollar.

**Net income attributable to H.B. Fuller:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Net income attributable to H.B. Fuller | $67.2 | $55.4 | 21.3% | $122.2 | $137.6 | (11.2)% |
| Percent of net revenue | 7.5% | 6.0% |  | 4.7% | 5.2% |  |

---

The net income attributable to H.B. Fuller in the third quarter of 2025 was $67.2 million compared to $55.4 million in the third quarter of 2024. The diluted earnings per share in the third quarter of 2025 was $1.22 per share as compared to $0.98 per share in the third quarter of 2024.

The net income attributable to H.B. Fuller in the first nine months of 2025 was $122.2 million compared to $137.6 million in the first nine months of 2024. The diluted earnings per share in the first nine months of 2025 was $2.21 per share as compared to $2.43 per share in the first nine months of 2024.

**Operating Segment Results**

As of November 30, 2024, our three operating segments consisted of Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. As of the beginning of fiscal 2025, we reorganized our operating segments by selling our NA Flooring business, previously part of the Construction Adhesives operating segment, and combining our Insulated Glass, Woodworking and Composite businesses, previously part of the Engineering Adhesives operating segment, with Construction Adhesives Roofing and Building Envelope and Infrastructure businesses to form the newly named Building Adhesive Solutions operating segment. All financial results related to NA Flooring have been moved to our Corporate Unallocated segment. Prior period segment information has been recast retrospectively to reflect the realignment.

The tables below provide certain information regarding the net revenue and operating income of each of our operating segments.

Corporate Unallocated amounts include business acquisition and integration costs, organizational restructuring charges and project costs associated with implementing a global Enterprise Resource Planning ("ERP") system that we refer to as Project ONE. As a result of the change in operating segments and the sale of our NA Flooring business, we have retrospectively moved the results of our Flooring business to Corporate Unallocated for prior periods.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30

------

[**Table of Contents**](#toc)

**Net Revenue by Segment:**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30, 2025** | **August 30, 2025** | **August 31, 2024** | **August 31, 2024** | **August 30, 2025** | **August 30, 2025** | **August 31, 2024** | **August 31, 2024** |
|  | **Net** | **% of** | **Net** | **% of** | **Net** | **% of** | **Net** | **% of** |
| ($ in millions) | **Revenue** | **Total** | **Revenue** | **Total** | **Revenue** | **Total** | **Revenue** | **Total** |
| Hygiene, Health and Consumable Adhesives | $**386.0** | **43%** | $390.0 | 42% | $**1151.8** | **45%** | $1151.4 | 44% |
| Engineering Adhesives | **272.3** | **31%** | 260.0 | 28% | **785.5** | **30%** | 743.7 | 28% |
| Building Adhesive Solutions | **233.7** | **26%** | 228.4 | 25% | **641.5** | **25%** | 630.6 | 24% |
| Segment total | $**892.0** | **100%** | $878.4 | 95% | $**2578.8** | **100%** | $2525.7 | 96% |
| Corporate Unallocated | **-** | **-** | 39.5 | 5% | **-** | **-** | 119.8 | 4% |
| Total | $**892.0** | **100%** | $917.9 | 100% | $**2578.8** | **100%** | $2645.5 | 100% |

---

**Segment Operating Income (Loss):**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30, 2025** | **August 30, 2025** | **August 31, 2024** | **August 31, 2024** | **August 30, 2025** | **August 30, 2025** | **August 31, 2024** | **August 31, 2024** |
|  | **Segment** |  | **Segment** |  | **Segment** |  | **Segment** |  |
|  | **Operating** |  | **Operating** |  | **Operating** |  | **Operating** |  |
|  | **Income** | **% of** | **Income** | **% of** | **Income** | **% of** | **Income** | **% of** |
| ($ in millions) | **(Loss)** | **Total** | **(Loss)** | **Total** | **(Loss)** | **Total** | **(Loss)** | **Total** |
| Hygiene, Health and Consumable Adhesives | $**46.5** | **42%** | $48.6 | 47% | $**119.8** | **47%** | $145.9 | 54% |
| Engineering Adhesives | **46.8** | **42%** | 40.1 | 38% | **121.9** | **47%** | 104.9 | 39% |
| Building Adhesive Solutions | **25.9** | **24%** | 26.0 | 25% | **54.5** | **21%** | 55.1 | 20% |
| Segment total | $**119.2** | **108%** | $114.7 | 110% | $**296.2** | **115%** | $305.9 | 113% |
| Corporate Unallocated | **(9.1)** | **(8)%** | (10.4) | (10)% | **(39.6)** | **(15)%** | (34.1) | (13)% |
| Total | $**110.1** | **100%** | $104.3 | 100% | $**256.6** | **100%** | $271.8 | 100% |

---

**Hygiene, Health and Consumable Adhesives**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Net revenue | $386.0 | $390.0 | (1.0)% | $1151.8 | $1151.4 | 0.0% |
| Segment operating income | $46.5 | $48.6 | (4.3)% | $119.8 | $145.9 | (17.9)% |
| Segment operating margin | 12.0% | 12.5% |  | 10.4% | 12.7% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31

------

[**Table of Contents**](#toc)

The following table provides details of the Hygiene, Health and Consumable Adhesives net revenue variances:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Nine Months Ended** |
|  | **August 30, 2025 vs. August 31, 2024** | **August 30, 2025 vs. August 31, 2024** |
| Organic growth | (3.1)% | 0.8% |
| M&A | 1.5% | 1.3% |
| Currency | 0.6% | (2.1)% |
| Total | (1.0)% | 0.0% |

---

Net revenue decreased 1.0 percent in the third quarter of 2025 compared to the third quarter of 2024. Organic growth decreased due to a decrease in sales volume, partially offset by an increase in product pricing. The 1.5 percent increase in net revenue from M&A was due to the acquisitions of GEM and Medifill in the first quarter of 2025. The positive currency effect was due to a stronger Euro and Egyptian pound, partially offset by a weaker Turkish lira compared to the U.S. dollar. As a percentage of net revenue, raw material costs decreased 90 basis points due to higher product pricing and the impact of acquisitions. Other manufacturing costs as a percentage of net revenue decreased 60 basis points compared to the prior year due to higher product pricing and the impact of acquisitions. SG&A expenses as a percentage of net revenue increased 200 basis points due to higher compensation costs and the impact of acquisitions. Segment operating income decreased 4.3 percent and segment operating margin as a percentage of net revenue decreased 50 basis points compared to the third quarter of 2024.

Net revenue was flat in the first nine months of 2025 compared to the first nine months of 2024. Organic growth increased due to an increase in product pricing, partially offset by a decrease in sales volume. The 1.3 percent increase in net revenue from M&A was due to the acquisitions of GEM and Medifill in the first quarter of 2025. The negative currency effect was due to a weaker Egyptian pound, Brazilian real and Mexican peso compared to the U.S. dollar. As a percentage of net revenue, raw material costs increased 110 basis points due to higher raw material costs partially offset by higher product pricing and the impact of acquisitions. Other manufacturing costs as a percentage of net revenue were flat compared to the prior year. SG&A expenses as a percentage of net revenue increased 120 basis points due to higher compensation costs and the impact of acquisitions. Segment operating income decreased 17.9 percent and segment operating margin as a percentage of net revenue decreased 230 basis points compared to the first nine months of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32

------

[**Table of Contents**](#toc)

**Engineering Adhesives**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Net revenue | $272.3 | $260.0 | 4.7% | $785.5 | $743.7 | 5.6% |
| Segment operating income | $46.8 | $40.1 | 16.7% | $121.9 | $104.9 | 16.2% |
| Segment operating margin | 17.2% | 15.4% |  | 15.5% | 14.1% |  |

---

The following tables provide details of the Engineering Adhesives net revenue variances:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Nine Months Ended** |
|  | **August 30, 2025 vs. August 31, 2024** | **August 30, 2025 vs. August 31, 2024** |
| Organic growth | 2.2% | 0.1% |
| M&A | 1.3% | 6.0% |
| Currency | 1.2% | (0.5)% |
| Total | 4.7% | 5.6% |

---

Net revenue increased 4.7 percent in the third quarter of 2025 compared to the third quarter of 2024. Organic growth increased due to an increase in both product pricing and sales volume. The 1.3 percent increase in net revenue from M&A was due to the acquisition of ND Industries Taiwan. The positive currency effect was due to a stronger Euro and British pound compared to the U.S. dollar. As a percentage of net revenue, raw material costs decreased 140 basis points primarily due to higher product pricing and the impact of acquisitions offset by higher raw material costs. Other manufacturing costs as a percentage of net revenue decreased 70 basis points due to the impact of higher sales volume offset by the impact of acquisitions. SG&A expenses as a percentage of net revenue increased 30 basis points. Segment operating income increased 16.7 percent and segment operating margin increased 180 basis points compared to the third quarter of 2024.

Net revenue increased 5.6 percent in the first nine months of 2025 compared to the first nine months of 2024. Organic growth increased due to an increase in product pricing, partially offset by a decrease in sales volume. The 6.0 percent increase in net revenue from M&A was due to the acquisition of ND Industries and ND Industries Taiwan. The negative currency effect was due to a weaker Chinese renminbi and Mexican peso, partially offset by a stronger Euro and British pound compared to the U.S. dollar. As a percentage of net revenue, raw material costs decreased 280 basis points due to higher product pricing and the impact of acquisitions. Other manufacturing costs as a percentage of net revenue increased 30 basis points. SG&A expenses as a percentage of net revenue increased 110 basis points primarily due to higher compensation and the impact of acquisitions. Segment operating income increased 16.2 percent and segment operating margin increased 140 basis points compared to the first nine months of 2024.

**Building Adhesive Solutions**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Net revenue | $233.7 | $228.4 | 2.3% | $641.5 | $630.6 | 1.7% |
| Segment operating income | $25.9 | $26.0 | (0.4)% | $54.5 | $55.1 | (1.1)% |
| Segment operating margin | 11.1% | 11.4% |  | 8.5% | 8.7% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33

------

[**Table of Contents**](#toc)

The following tables provide details of the Building Adhesive Solutions net revenue variances:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Nine Months Ended** |
|  | **August 30, 2025 vs. August 31, 2024** | **August 30, 2025 vs. August 31, 2024** |
| Organic growth | (1.0)% | 0.0% |
| M&A | 1.7% | 2.0% |
| Currency | 1.6% | (0.3)% |
| Total | 2.3% | 1.7% |

---

Net revenue increased 2.3 percent in the third quarter of 2025 compared to the third quarter of 2024. Organic growth decreased due to a decrease in sales volume partially offset by an increase in product pricing. The 1.7 percent increase in net revenue from M&A was due to the acquisition of HS Butyl in the third quarter of 2024. The positive currency effect was due to a stronger Euro and British pound compared to the U.S. dollar. As a percentage of net revenue, raw material costs decreased 40 basis points. Other manufacturing costs as a percentage of net revenue increased 30 basis points. SG&A expenses as a percentage of net revenue increased 40 basis points. Segment operating income decreased 0.4 percent and segment operating margin decreased 30 basis points compared to the third quarter of 2024.

Net revenue increased 1.7 percent in the first nine months of 2025 compared to the first nine months of 2024. Organic growth was flat due to a decrease in sales volume offset by an increase in product pricing. The 2.0 percent increase in net revenue from M&A was due to the acquisition of HS Butyl in the third quarter of 2024. The negative currency effect was due to a weaker Turkish lira and Australia dollar, partially offset by the Euro and British pound, compared to the U.S. dollar. As a percentage of net revenue, raw material costs decreased 40 basis points. Other manufacturing costs as a percentage of net revenue increased 10 basis points. SG&A expenses as a percentage of net revenue increased 50 basis points. Segment operating income decreased 1.1 percent and segment operating margin decreased 20 basis points compared to the first nine months of 2024.

**Corporate Unallocated**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** | **2025 vs** | **August 30,** | **August 31,** | **2025 vs** |
| ($ in millions) | **2025** | **2024** | **2024** | **2025** | **2024** | **2024** |
| Net revenue | $- | $39.5 | (100.0)% | $- | $119.8 | (100.0)% |
| Segment operating loss | $(9.1) | $(10.4) | (12.5)% | $(39.6) | $(34.1) | 16.1% |
| Segment operating margin | NMP | -26.3% |  | NMP | -28.5% |  |

---

NMP = Non-meaningful percentage

Corporate Unallocated amounts include business acquisition and integration costs, organizational restructuring charges and project costs associated with implementing a global Enterprise Resource Planning ("ERP") system that we refer to as Project ONE. As a result of the change in operating segments and the sale of our NA Flooring business, we have retrospectively moved the results of our Flooring business to Corporate Unallocated for prior periods.

Segment operating loss in the third quarter of 2025 decreased 12.5 percent compared to the third quarter of 2024 due to the inclusion of the NA Flooring business results in 2024.

Segment operating loss in the first nine months of 2025 increased 16.1 percent compared to the first nine months of 2024 due to higher acquisition project in costs and the inclusion of the NA Flooring business results in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34

------

[**Table of Contents**](#toc)

**Financial Condition, Liquidity and Capital Resources**

Total cash and cash equivalents as of August 30, 2025 were $122.5 million compared to $169.4 million as of November 30, 2024 and $131.4 million as of August 31, 2024. The majority of the $122.5 million in cash and cash equivalents as of August 30, 2025 was held outside the United States. Total long and short-term debt was $2,080.5 million as of August 30, 2025, $2,010.6 million as of November 30, 2024 and $2,021.1 million as of August 31, 2024. The total debt to total capital ratio as measured by total debt divided by total debt plus total stockholders' equity was 51.5 percent as of August 30, 2025 as compared to 50.8 percent as of November 30, 2024 and 52.3 percent as of August 31, 2024.

We believe that cash flows from operating activities will be adequate to meet our short-term and long-term liquidity and capital expenditure needs. In addition, we believe we have the ability to obtain both short-term and long-term debt to meet our financing needs for the foreseeable future. Cash available in the United States has historically been sufficient and we expect it will continue to be sufficient to fund U.S. operations, U.S. capital spending and U.S. pension and other postretirement benefit contributions in addition to funding U.S. acquisitions, dividend payments, debt service and share repurchases as needed. For those international earnings considered to be reinvested indefinitely, we currently have no intention to, and plans do not indicate a need to, repatriate these funds for U.S. operations.

Our credit agreements include restrictive covenants that, if not met, could lead to a renegotiation of our credit lines and a significant increase in our cost of financing. As of August 30, 2025, we were in compliance with all covenants of our contractual obligations as shown in the following table:

---

| | | | |
|:---|:---|:---|:---|
| **Covenant** | **Debt Instrument** | **Measurement** | **Result as of August 30, 2025** |
| Secured Total Indebtedness / TTM<sup>1</sup> EBITDA | Revolving Facility and Term Loan A Facility | Not greater than 4.50<sup>2</sup> | 2.4 |
| TTM<sup>1</sup> EBITDA / Consolidated Interest Expense | Revolving Facility and Term Loan A Facility | Not less than 2.0 | 4.8 |

---

<sup>1</sup> TTM = Trailing 12 months

EBITDA for covenant purposes is defined as consolidated net income, plus (i) interest expense, (ii) expense for taxes paid or accrued, (iii) depreciation and amortization, (iv) certain non-cash impairment losses, (v) extraordinary non-cash losses incurred other than in the ordinary course of business, (vi) nonrecurring extraordinary non-cash restructuring charges and the non-cash impact of purchase accounting, (vii) any non-cash charge for the excess of rent expense over actual cash rent paid due to the use of straight-line rent, non-cash charge pursuant to any management equity plan, stock option plan or any other management or employee benefit, (viii) any non-cash finance charges in respect of any pension liabilities or other provisions and income (loss) attributable to deferred compensation plans, (ix) any non-recurring or unusual cash restructuring charges and operating improvements, (x) cost savings initiative and cost synergies related to acquisitions within 12 months, (xi) non-capitalized charges relating to the Company's SAP implementation, (xii) fees, costs, expenses and charges incurred in connection with the financing, (xiii) fees, costs, expenses, make-whole or penalty payments and other similar items arising out of acquisitions, investments and dispositions, the incurrence, issuance, repayment or refinancing of indebtedness and any issuance of equity interests; minus, non-recurring or unusual non-cash gains incurred not in the ordinary course of business. Provided that the aggregate amounts that may be added back for any period pursuant to clauses (ix), (x) and (xi) shall not exceed 15% of EBITDA for such period (calculated prior to giving effect to all addbacks and adjustments). For Secured Total Indebtedness / TTM EBITDA ratio, TTM EBITDA is adjusted for the pro forma results from Material Acquisitions and Material Divestitures, both as defined in the Second Amended and Restated Credit Agreement, as if the acquisition or divestiture occurred at the beginning of the calculation period. The full definition is set forth in the Second Amended and Restated Credit Agreement filed as an exhibit to the Company's 8-K filing dated February 21, 2023.

Consolidated Interest Expense for covenant purposes is defined as the interest expense (including without limitation to the portion of capital lease obligations that constitutes imputed interest in accordance with GAAP) of the Company and its subsidiaries calculated on a consolidated basis for such period with respect to all outstanding indebtedness allocable to such period in accordance with GAAP, including net costs (or benefits) under Interest Rate Swap Agreements and commissions, discounts and other fees and charges with respect to letters of credit and the interest component of all Attributable Receivables Indebtedness.

We believe we have the ability to meet all of our contractual obligations and commitments for the next twelve months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35

------

[**Table of Contents**](#toc)

**Selected Metrics of Liquidity**

Key metrics we monitor are net working capital as a percent of annualized net revenue, trade receivable days sales outstanding ("DSO"), inventory days on hand, trade accounts payable outstanding ("DPO") free cash flow after dividends and debt capitalization ratio.

---

| | | |
|:---|:---|:---|
|  | **August 30,** | **August 31,** |
|  | **2025** | **2024** |
| Net working capital as a percentage of annualized net revenue<sup>1</sup> | 17.0% | 16.1% |
| Accounts receivable DSO (in days)<sup>2</sup> | 57 | 57 |
| Inventory days on hand (in days)<sup>3</sup> | 78 | 75 |
| Trade accounts payable DPO (in days)<sup>4</sup> | 69 | 70 |
| Free cash flow<sup>5</sup> | $62.2 | $104.0 |
| Total debt to total capital ratio<sup>6</sup> | 51.5% | 52.3% |

---

<sup>1</sup> Current quarter net working capital (trade receivables, net of allowance for doubtful accounts plus inventory minus trade payables) divided by annualized net revenue (current quarter multiplied by four).

<sup>2</sup> Trade receivables net of the allowance for doubtful accounts at the balance sheet date multiplied by 91 (13 weeks) and divided by the net revenue for the quarter.

<sup>3</sup> Total inventory multiplied by 91 (13 weeks) and divided by cost of sales (excluding delivery costs) for the quarter.

<sup>4</sup> Trade accounts payable multiplied by 91 (13 weeks) and divided by the net revenue for the quarter.

<sup>5</sup> Year-to-date net cash provided by operating activities, less purchased property, plant and equipment. See reconciliation of net cash provided by operating activities to free cash flow.

<sup>6</sup> Total debt divided by (total debt plus total stockholders' equity).

Free cash flow, a non-GAAP financial measure, is defined as net cash provided by operating activities less purchased property, plant and equipment. Free cash flow is an integral financial measure used by the Company to assess its ability to generate cash in excess of its operating needs, therefore, the Company believes this financial measure provides useful information to investors. The following table reflects the manner in which free cash flow is determined and provides a reconciliation of free cash flow to net cash provided by operating activities, the most directly comparable financial measure calculated and reported in accordance with U.S. GAAP.

**Reconciliation of "Net cash provided by operating activities" to free cash flow**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
| **($ in millions)** | **August 30, 2025** | **August 31, 2024** |
| Net cash provided by operating activities | $156.8 | $216.8 |
| Less: Purchased property, plant and equipment | 94.6 | 112.8 |
| Free cash flow | $62.2 | $104.0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36

------

[**Table of Contents**](#toc)

**Summary of Cash Flows**

**Cash Flows from Operating Activities:**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** |
| ($ in millions) | **2025** | **2024** |
| Net cash provided by operating activities | $156.8 | $216.8 |

---

Net income including non-controlling interest was $122.3 million in the first nine months of 2025 compared to $137.6 million in the first nine months of 2024. Depreciation and amortization expense totaled $132.8 million in the first nine months of 2025 compared to $128.7 million in the first nine months of 2024. Deferred income taxes was a use of cash of $39.2 million in the first nine months of 2025 compared to $46.0 million in the first nine months of 2024. Accrued compensation was a use of cash of $19.2 million in 2025 compared to $11.6 million in 2024. Other assets was a use of cash of $7.5 million in the first nine months of 2025 compared to $39.0 million in the first nine months of 2024. Other liabilities was a source of cash of $28.6 million in the first nine months of 2025 compared to $0.9 million in the first nine months of 2024.

Changes in net working capital (trade receivables, inventory and trade payables) accounted for a use of cash of $71.2 million compared to a source of cash of $13.9 million last year. The table below provides the cash flow impact due to changes in the components of net working capital and an assessment of each of the components:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** |
| ($ in millions) | **2025** | **2024** |
| Trade receivables, net | $(3.3) | $26.4 |
| Inventory | (42.1) | (62.2) |
| Trade payables | (25.8) | 49.7 |
| Total cash flow impact | $(71.2) | $13.9 |

---

● Trade receivables, net – Trade receivables, net was a use of cash of $3.3 million and a source of cash of $26.4 million in the first nine months of 2025 and 2024, respectively. The use of cash in 2025 compared to source of cash in 2024 was due to less cash collected on trade receivables in the current year compared to the prior year. The DSO were 57 days at August 30, 2025 and 57 days at August 31, 2024. 

● Inventory – Inventory was a use of cash of $42.1 million and $62.2 million in the first nine months of 2025 and 2024, respectively. The lower use of cash in 2025 compared to 2024 was due to lower inventory purchases in 2025 compared to 2024. Inventory days on hand were 78 days as of August 30, 2025 and 75 days as of August 31, 2024.

● Trade payables – Trade payables was a use of cash of $25.8 million and a source of cash of $49.7 million in the first nine months of 2025 and 2024, respectively. The use of cash in 2025 compared to source of cash in 2024 reflects higher payments on trade payables in the current year compared to the prior year. Days payable outstanding were 69 days as of August 30, 2025 and 70 days as of August 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37

------

[**Table of Contents**](#toc)

**Cash Flows from Investing Activities:**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** |
| ($ in millions) | **2025** | **2024** |
| Net cash used in investing activities | $**(182.7**) | $(385.8) |

---

Purchases of property, plant and equipment were $94.6 million during the first nine months of 2025 compared to $112.8 million for the same period of 2024. This difference reflects the timing of capital projects and expenditures related to growth initiatives.

During the first nine months of 2025, we paid $162.1 million of cash for business acquisitions. Additionally, we received $75.7 million in cash related to the sale of our NA Flooring business. During the first nine months of 2024, we paid $274.1 million of cash for business acquisitions.

**Cash Flows from Financing Activities:**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **August 30,** | **August 31,** |
| ($ in millions) | **2025** | **2024** |
| Net cash provided by financing activities | $(33.7) | $131.6 |

---

In the first nine months of 2025, borrowings on our revolving credit facility were $1,114.3 million and repayments on our revolving credit facility and our long-term debt totaled $1,053.6 million. These borrowings are for general working capital purposes and permitted acquisitions. Borrowings on our revolving credit facility were $1,732.9 and repayments on our revolving credit facility and our long-term debt totaled $1,556.1 million in the first nine months of 2024. Net payments of notes payable were a use of cash of $0.6 million in the first nine months of 2025 compared to $1.0 million in the same period of 2024. Cash dividends paid were $37.6 million in the first nine months of 2025 compared to $35.4 million in the same period of 2024. Repurchases of common stock were $60.7 million in the first nine months of 2025 compared to $39.4 million in the same period of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38

------

[**Table of Contents**](#toc)

**Forward-Looking Statements and Risk Factors**

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "intend," "estimate," "will," "should," "could" (including the negative or variations thereof) and other expressions that indicate future events and trends. These plans and expectations are based upon certain underlying assumptions, including those mentioned with the specific statements. Such assumptions are in turn based upon internal estimates and analyses of current market conditions and trends, our plans and strategies, economic conditions and other factors. These plans and expectations and the assumptions underlying them are necessarily subject to risks and uncertainties inherent in projecting future conditions and results. Actual results could differ materially from expectations expressed in the forward-looking statements if one or more of the underlying assumptions and expectations proves to be inaccurate or is unrealized. In addition to the factors described in this report, Item 1A. Risk Factors identifies some of the important factors that could cause our actual results to differ materially from those in any such forward-looking statements. In order to comply with the terms of the safe harbor, we have identified these important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from the anticipated results or other expectations expressed in the forward-looking statements. These factors should be considered, together with any similar risk factors or other cautionary language that may be made elsewhere in this Quarterly Report on Form 10-Q.

The list of important factors in Item 1A. Risk Factors does not necessarily present the risk factors in order of importance. This disclosure, including that under Forward-Looking Statements and Risk Factors, and other forward-looking statements and related disclosures made by us in this report and elsewhere from time to time, represents our best judgment as of the date the information is given. We do not undertake responsibility for updating any of such information, whether as a result of new information, future events, or otherwise, except as required by law. Investors are advised, however, to consult any further public company disclosures (such as in filings with the SEC or in our press releases) on related subjects.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

We are exposed to various market risks, including changes in interest rates, foreign currency rates and prices of raw materials. Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and foreign currency exchange rates. See Part II, Item 7A in our Annual Report on Form 10-K for the year ended November 30, 2024 for further discussion of these market risks. There have been no material changes in the reported market risk of the Company since November 30, 2024.

**Item 4. Controls and Procedures**

*Controls and Procedures*

We conducted an evaluation, under the supervision and with the participation of our president and chief executive officer and executive vice president, chief financial officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act)) as of August 30, 2025. Based on this evaluation, our president and chief executive officer and executive vice president, chief financial officer concluded that, as of August 30, 2025, our disclosure controls and procedures were effective.

For purposes of Rule 13a-15(e), the term *disclosure controls and procedures* means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its president and chief executive officer and executive vice president, chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control over Financial Reporting*

 

There were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39

------

[**Table of Contents**](#toc)

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

*Environmental Matters*

We are involved in environmental investigations, clean-up activities and administrative proceedings related to environmental compliance matters at former and current operating facilities. We have also been identified as a potentially responsible party ("PRP") under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) and/or similar state laws that impose liability for costs relating to the clean up of contamination resulting from past spills, disposal or other release of hazardous substances associated with landfills and/or hazardous waste sites. As a PRP, we may be required to pay a share of the costs of investigation and clean-up of these sites. We are subject to similar laws in some of the countries where current and former facilities are located. Our environmental, health and safety department monitors compliance with applicable laws on a global basis.

To the extent we can reasonably estimate the amount of our probable liabilities for environmental matters, we establish a financial provision.

While uncertainties exist with respect to the amounts and timing of the ultimate environmental liabilities, based on currently available information, we have concluded that these matters, individually or in the aggregate, will not have a material adverse effect on our results of operations, financial condition or cash flow.

*Other Legal Proceedings*

From time to time and in the ordinary course of business, we are a party to, or a target of, lawsuits, claims, investigations and proceedings, including product liability, personal injury, contract, patent and intellectual property, environmental, health and safety, tax and employment matters. While we are unable to predict the outcome of these matters, we have concluded, based upon currently available information, that the ultimate resolution of any pending matter, individually or in the aggregate, including asbestos-related litigation, will not have a material adverse effect on our results of operations, financial condition or cash flow. However, adverse developments and/or periodic settlements could negatively impact the results of operations or cash flows in one or more future periods.

For additional information regarding environmental matters and other legal proceedings, see Note 13 to our Consolidated Financial Statements.

**Item 1A. Risk Factors**

This Form 10-Q contains forward-looking statements concerning our future programs, products, expenses, revenue, liquidity and cash needs as well as our plans and strategies. These forward-looking statements are based on current expectations and we assume no obligation to update this information. Numerous factors could cause actual results to differ significantly from the results described in these forward-looking statements, including the risk factors identified under Part I, Item 1A. Risk Factors contained in our Annual Report on Form 10-K for the fiscal year ended November 30, 2024. There have been no material changes in the risk factors disclosed by us under Part I, Item 1A. Risk Factors contained in the Annual Report on Form 10-K for the fiscal year ended November 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40

------

[**Table of Contents**](#toc)

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Issuer Purchases of Equity Securities**

Information on our purchase of equity securities during the quarter ended August 30, 2025 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  |  | **(d)** |
|  |  |  | **(c)** | **Maximum** |
|  |  |  | **Number of** | **Approximate Dollar** |
|  | **(a)** |  | **Shares** | **Value of Shares that** |
|  | **Total** | **(b)** | **Purchased** | **may yet be** |
|  | **Number of** | **Average** | **as Part of** | **Purchased Under the** |
|  | **Shares** | **Price Paid** | **Publicly Announced** | **Plan or Program** |
| **Period** | **Purchased** | **per Share** | **Plan or Program** | **(millions)** |
| June 1, 2025 - July 5, 2025 |  | $- |  | $211 |
| July 6, 2025 - August 2, 2025 |  | $- |  | $211 |
| August 3, 2025 - August 30, 2025 |  | $- |  | $211 |

---

On April 7, 2022, the Board of Directors authorized a new share repurchase program of up to $300.0 million of our outstanding common shares for a period of up to five years. Under the program, we are authorized to repurchase shares for cash on the open market, from time to time, in privately negotiated transactions or block transactions, or through an accelerated repurchase agreement. The timing of such repurchases is dependent on price, market conditions and applicable regulatory requirements.

**Item *5.* Other Information**

**Rule *10b5*-*1* Plan Adoptions and Modifications**

None.

**Item 6. Exhibits**

---

| | |
|:---|:---|
| 31.1 | [Form of 302 Certification – Celeste B. Mastin](ex_836324.htm) |
| 31.2 | [Form of 302 Certification – John J. Corkrean](ex_836325.htm) |
| 32.1 | [Form of 906 Certification – Celeste B. Mastin](ex_836326.htm) |
| 32.2 | [Form of 906 Certification – John J. Corkrean](ex_836327.htm) |
| 101 | The following materials from the H.B. Fuller Company Quarterly Report on Form 10-Q for the quarter ended August 30, 2025 formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Total Equity, (v) the Consolidated Statements of Cash Flows and (vi) the Notes to Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

\* Asterisked items are management contracts or compensatory plans or arrangements required to be filed.

<sup>(1)</sup> Incorporated by reference to Appendix B to the H.B. Fuller Company Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 4, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **H.B. Fuller Company** | **H.B. Fuller Company** |
| Dated: September 25, 2025 |  | /s/ John J. Corkrean |
|  |  | John J. Corkrean |
|  |  | Executive Vice President, |
|  |  | Chief Financial Officer |

---

**Exhibit Index**

Exhibits

---

| | |
|:---|:---|
| 31.1 | Form of 302 Certification – Celeste B. Mastin |
| 31.2 | Form of 302 Certification – John J. Corkrean |
| 32.1 | Form of 906 Certification – Celeste B. Mastin |
| 32.2 | Form of 906 Certification – John J. Corkrean |
| 101 | The following materials from the H.B. Fuller Company Quarterly Report on Form 10-Q for the quarter ended August 30, 2025 formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Total Equity, (v) the Consolidated Statements of Cash Flows and (vi) the Notes to Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

\* Asterisked items are management contracts or compensatory plans or arrangements required to be filed.

<sup>(1)</sup> Incorporated by reference to Appendix B to the H.B. Fuller Company Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 4, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

I, Celeste B. Mastin, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this report on Form 10-Q of H.B. Fuller Company;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-115(e) and 15d-115(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d–15(f)) for the registrant and have:

---

| | |
|:---|:---|
| a.) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |

---

---

| | |
|:---|:---|
| b.) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |

---

c.) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

---

| | |
|:---|:---|
| d.) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |

---

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: September 25, 2025<br>/s/ Celeste B. Mastin |
| Celeste B. Mastin<br> President and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

I, John J. Corkrean, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this report on Form 10-Q of H.B. Fuller Company;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-115(e) and 15d-115(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d–15(f)) for the registrant and have:

---

| | |
|:---|:---|
| a.) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |

---

---

| | |
|:---|:---|
| b.) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |

---

c.) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

---

| | |
|:---|:---|
| d.) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |

---

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: September 25, 2025<br>/s/ John J. Corkrean |
| John J. Corkrean<br> Executive Vice President, Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION**

I, Celeste B. Mastin, in connection with the Quarterly Report of H.B. Fuller Company on Form 10-Q for the quarter ended August 30, 2025 (the "Report"), hereby certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of H.B. Fuller Company.

Date: September 25, 2025

---

| |
|:---|
| /s/ Celeste B. Mastin |
| Celeste B. Mastin<br> President and Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION**

I, John J. Corkrean, in connection with the Quarterly Report of H.B. Fuller Company on Form 10-Q for the quarter ended August 30, 2025 (the "Report"), hereby certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of H.B. Fuller Company.

Date: September 25, 2025

---

| |
|:---|
| /s/ John J. Corkrean |
| John J. Corkrean<br> Executive Vice President, Chief Financial Officer |

---